Combined vaccines for prevention of porcine virus infections

This application is a national stage application under 35 U.S.C. .sctn.371 of PCT International Application No. PCT/CN2012/076125, filed May 25, 2012, which claims the benefit of China Patent Application Nos. CN201110331159.8, filed Oct. 27, 2011, CN201110331206.9, filed Oct. 27, 2011, and CN201110140951.5, filed 27 May 2011, which are hereby incorporated by reference in its entirety.

CROSS-REFERENCE TO RELATED APPLICATIONS

The present applications claims priority to the following three Chinese patent applications: 201110140951.5, filed on May 27, 2011, entitled "Combination Vaccines for Porcine Reproductive and Respiratory Syndrome and Classical Swine Fever and Uses Thereof," 201110331206.9, filed on Oct. 27, 2011, entitled "Combination Vaccines for Porcine Reproductive and Respiratory Syndrome and Porcine Pseudorabies Virus and Uses Thereof," 201110331159.8, filed on Oct. 27, 2011, entitled "Triple Combination Vaccines for Porcine Reproductive and Respiratory Syndrome, Classical Swine Fever and Porcine Pseudorabies Virus and Preparation Methods Thereof," which are incorporated herein by reference to their entirety.

FIELD OF THE INVENTION

The present invention relates to veterinary biological products, particularly to the live combination vaccine for preventing porcine reproductive and respiratory syndrome, classical swine fever and porcine pseudorabies virus, and preparations thereof.

BACKGROUND OF THE INVENTION

Porcine reproductive and respiratory syndrome (PRRS) is one of the major infectious diseases threatening pig industry in many places around the world. Ever since the outbreak of highly-pathogenic porcine reproductive and respiratory syndrome (also called highly-pathogenic blue ear disease) in China in 2006, PRRS has caused huge economic loss to Chinese pig industry, and is listed by Chinese Ministry of Agriculture as one of the diseases for which compulsory vaccination is required.

In addition to PRRS, pigs can be further infected by other infectious diseases such as classical swine fever (CSF) and pseudorabies. However, PRRS virus (PRRSV) is known to induce immune suppression after infecting its host, and therefore usually result in reduced immune response to secondary infections or even vaccination failure. Studies have shown that PRRSV impairs host immune system by, for example, destroying alveolar macrophages that are important for generating immune response, and/or suppressing cytokine expression that confers immunological defense to secondary infections. For example, PRRSV infection has been found to significantly inhibit host immune response to Classical Swine Fever Virus (CSFV) vaccine, even resulting in CSFV vaccination failure (Suradhat, S. et al, Vaccine, 24: 2634-3642 (2006); Li, H. et al, Veterinary Microbiology, 95: 295-301 (2003)). Co-vaccination of attenuated PRRSV and attenuated CSFV is reported to have a reduced immuno-protection rate of about 60%, which fails to meet the vaccination requirement. To vaccinate against the two pathogens, individual vaccinations separated by a 14-day interval are required (see, e.g. Du, X. Z. et al, Zhejiang Journal Animal Science and Veterinary Medicine, 2: p 5-6 (2011)). For another example, PRRSV has been found to negatively affect the vaccination effects of Pseudorabies Virus (PRV), and significantly reduce or delay the host immune response against PRV (De Bruin, M. G. M. et al, Veterinary Immunology and Immunopathology, 76(1-2): p 125-135 (2000)).

The immuno-inhibition of PRRSV tends to complicate the vaccination regimen for pigs, and reduce the vaccination efficacy and efficiency. When pigs are vaccinated against PRRSV and other viruses, it is often necessary to apply repetitive injections and multiple dosages, making the vaccination process time-consuming, labor-intensive, and costly. Moreover, in a multiple vaccination regimen, a missing dose can have a direct impact on the protection efficacy of the vaccines, while frequent and repeated vaccinations can result in immuno-paralysis, and induce immunological stress.

Therefore, there exists great need for a combined vaccine composition for PRRSV and other pig infectious diseases, without substantial immuno-inhibition.

SUMMARY OF THE INVENTION

One aspect of the present disclosure relates to vaccine compositions, comprising a Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) vaccine and a second porcine virus vaccine, wherein the PRRSV vaccine and the second vaccine are substantially free from immuno-inhibition against each other. In certain embodiments, the vaccine composition further comprises a third porcine virus vaccine, wherein the PRRSV vaccine, the second vaccine and the third vaccine are substantially free from immuno-inhibition against each other.

In certain embodiments, the second porcine virus vaccine is selected from Classical Swine Fever Virus (CSFV) vaccine and Pseudorabies Virus (PRV) vaccine. In certain embodiments, the third porcine virus vaccine is selected from Classical Swine Fever Virus (CSFV) vaccine and Pseudorabies Virus (PRV) vaccine. The second vaccine is different from the third vaccine.

In certain embodiments, the vaccine compositions comprise a PRRSV vaccine, a CSFV vaccine and a PRV vaccine, wherein the PRRSV vaccine, the CSFV vaccine and the PRV vaccine are substantially free from immuno-inhibition against each other.

In certain embodiments, the PRRSV vaccine comprises an attenuated PRRSV. In certain embodiments, the attenuated PRRSV comprises an Nsp2 nucleotide encoded by a DNA sequence which, when compared with SEQ ID NO: 4, lacks a nucleotide fragment comprising at least 50 contiguous nucleotides, wherein the fragment is at least about 80% homologous to an equal length portion of SEQ ID NO: 8. In certain embodiments, the DNA fragment comprises at least 100, at least 120, at least 150, at least 180, at least 200, at least 210, at least 220, at least 230, at least 240, at least 250, at least 260, at least 270, at least 280, at least 290, at least 300, at least 310, at least 320, at least 330, at least 340, at least 350, or at least 360 contiguous nucleotides. In certain embodiments, the DNA fragment is at least about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or 100% homologous to an equal length portion of SEQ ID NO: 8. In certain embodiments, the DNA fragment comprises SEQ ID NO: 8.

In certain embodiments, the attenuated PRRSV comprises an Nsp2 nucleotide encoding for a Nsp2 protein sequence which, when compared with SEQ ID NO: 11, lacks a peptide fragment comprising at least 20 contiguous amino acids, wherein the fragment is at least about 80% homologous to an equal length portion of SEQ ID NO: 9. In certain embodiments, the peptide fragment comprises at least 30, at least 40, at least 50, at least 60, at least 70, at least 75, at least 80, at least 85, at least 90, at least 95, at least 100, at least 105, at least 110, at least 115, or at least 120 contiguous amino acids. In certain embodiments, the peptide fragment is at least about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or 100% homologous to an equal length portion of SEQ ID NO: 9. In certain embodiments, the peptide fragment comprises SEQ ID NO: 9.

In certain embodiments, the attenuated PRRSV is attenuated from a highly-pathogenic PRRSV. In certain embodiments, the attenuated PRRSV comprises an Nsp2 nucleotide encoded by a DNA sequence which, when compared with SEQ ID NO: 5, lacks discontinuous 90 nucleotides within SEQ ID NO: 6. In certain embodiments, the Nsp2 nucleotide is encoded by a sequence having at least 90% homology to SEQ ID NO: 2. In certain embodiments, the Nsp2 nucleotide is encoded by a sequence comprising SEQ ID NO: 2.

In certain embodiments, the attenuated PRRSV further comprises an Nsp1 nucleotide sequence, which is encoded by a sequence having at least 90% homology to SEQ ID NO: 1. In certain embodiments, the attenuated PRRSV comprises an Nsp1 nucleotide sequence encoded by SEQ ID NO: 1, and an Nsp2 nucleotide sequence encoded by SEQ ID NO: 2.

In certain embodiments, the attenuated PRRSV comprises a PRRSV nucleotide sequence encoded by a sequence having at least 90% homology to SEQ ID NO: 3. In certain embodiments, the attenuated PRRSV comprises a PRRSV nucleotide sequence encoded by SEQ ID NO: 3. In certain embodiments, the attenuated PRRSV has a microorganism deposit number of CGMCC No.: 3121.

In certain embodiments, the CSFV vaccine comprises an attenuated CSFV. In certain embodiments, the attenuated CSFV is encoded by a sequence having at least 80% homology to SEQ ID NO: 10. In certain embodiments, the attenuated CSFV is encoded by SEQ ID NO: 10. In certain embodiments, the attenuated CSFV has a microorganism deposit number of CGMCC No.: 3891.

In certain embodiments, the PRV vaccine comprises an attenuated PRV. In certain embodiments, the attenuated PRV comprises a sequence having at least 80% homology to a sequence having an NCBI reference number of NC 006151.

In certain embodiments, the attenuated PRV has one or more inactivated genes selected from the group consisting of TK, PK, RR, dUTPase, gG, gC, gE, gD and gI. In certain embodiments, the attenuated PRV has an inactivated gE gene. In certain embodiments, the attenuated PRV has a microorganism deposit number of CGMCC No.: 5076.

In certain embodiments, the vaccine composition provided herein comprises an immunologically effective amount of the PRRSV vaccine, the CSFV vaccine and/or the PRV vaccine. In certain embodiments, the immunologically effective amount of the PRRSV vaccine is at least 10.sup.4.5 TCID.sub.50, 10.sup.5.0 TCID.sub.50, or 10.sup.5.5 TCID.sub.50, the immunologically effective amount of the CSFV vaccine is at least 10.sup.0.5 FA-TCID.sub.50 (fluorescent antibody--TCID.sub.50), 10.sup.1.0 FA-TCID.sub.50, 10.sup.1.5 FA-TCID.sub.50, 10.sup.2.0 FA-TCID.sub.50, 10.sup.2.5 FA-TCID.sub.50, 10.sup.3.0 TCID.sub.50, 10.sup.3.5 FA-TCID.sub.50, 10.sup.4.0 FA-TCID.sub.50, 10.sup.4.5 FA-TCID.sub.50, or 10.sup.5.0 FA-TCID.sub.50, or is at least 2.5 RID (rabbit infective dose), 3 RID, 5 RID, 10 RID, 30 RID, 100 RID, 150 RID, 300 RID, 750 RID, 1000 RID, 3000 RID, or 7500 RID, and/or the immunologically effective amount of the PRV vaccine is at least 10.sup.3.0 TCID.sub.50, 10.sup.3.5 TCID.sub.50, 10.sup.4.0 TCID.sub.50, 10.sup.4.5 TCID.sub.50, 10.sup.5.0 TCID.sub.50, 10.sup.5.5 TCID.sub.50 or 10.sup.6.0 TCID.sub.50.

In certain embodiments, the TCID.sub.50 ratio of the PRRSV vaccine to the CSFV vaccine in the combined vaccine ranges from 10000:1 to 1:1. In certain embodiments, the TCID.sub.50 ratio of the PRRSV vaccine to the PRV vaccine in the combined vaccine ranges from 1:1 to 1:30. In certain embodiments, the TCID.sub.50 ratio of the PRRSV vaccine:the CSFV vaccine:the PRV vaccine in the combined vaccine ranges from about 10.sup.4:1:10.sup.5 to about 5:1:6.

In certain embodiments, the vaccine compositions further comprises an adjuvant. In certain embodiments, the vaccine compositions further comprises a cryoprotectant. In certain embodiments, the cryoprotectant comprises sucrose, L-sodium glutamate, and/or lactalbumin hydrolysate.

In another aspect, the present disclosure provides methods for preparing the vaccine compositions provided herein, comprising: (a) collecting PRRSV vaccine strain, CSFV vaccine strain and/or PRV vaccine strain, which are cultivated in their respective susceptible cells, and (b) mixing two or more of the virus strains at a suitable TCID.sub.50 ratio.

In certain embodiments, the susceptible cells for the PRRSV vaccine strain is a cell line selected from the group consisting of Marc-145, MA-104, Vero, and CL-2621, or a primary cell which is PAM cell. In certain embodiments, the susceptible cells for the CSFV vaccine strain is a cell line selected from the group consisting of BT, Vero, MPK, SK6, PK2a, CPK, RKC, MDBK, MDCK, CRFK, ST, and PT, or a primary cell which is BT cell. In certain embodiments, the susceptible cells for the PRV vaccine strain is a cell line selected from the group consisting of ST, PK-15, Marc-145, MDBK, BT, Vero, BHK-21, porcine kidney cell line (IBRS-2), rabbit kidney cell line (RK), and chicken embryo fibroblast cell line, or a primary cell which is porcine kidney primary cell.

In certain embodiments, the cultivation comprises inoculating each vaccine strain to its susceptible cells at a cell density ranging from 1.times.10.sup.6/ml-5.times.10.sup.6/ml in a roller bottle culture, or at a cell density ranging from 5.times.10.sup.6/ml-1.times.10.sup.7/ml in a suspension culture with an introduced adherent carrier in a bioreactor.

In certain embodiments, the PRRSV vaccine strain is inoculated at a Multiplicity of Infection (MOI) of 0.01-0.5, the CSFV vaccine strain is inoculated at a MOI of 0.1-0.5, and/or the PRV vaccine strain is inoculated at a MOI of 0.005-0.5.

In certain embodiments, the step (b) comprises mixing the collected PRRSV vaccine virus with the CSFV vaccine virus at a TCID.sub.50 ratio from 10000:1 to 1:1. In certain embodiments, the step (b) comprises mixing the collected PRRSV vaccine virus with the PRV vaccine virus at a TCID.sub.50 ratio from 1:1 to 1:30. In certain embodiments, the step (b) comprises mixing the collected PRRSV vaccine virus, the CSFV vaccine virus, and the PRV vaccine virus at a TCID.sub.50 ratio from 10.sup.4:1:10.sup.5 to about 5:1:6.

In certain embodiments, the step (b) further comprises mixing the mixture of the collected virus solutions with a cryoprotectant. In certain embodiments, the mixture of the collected virus solutions is mixed with the cryoprotectant in a volume ratio of 75-80:25-20.

In another aspect, the present disclosure provides vaccine compositions prepared using the methods provided herein.

In another aspect, the present disclosure provides use of the vaccine compositions provided herein in the manufacture of a medicament for preventing or treating PRRS, CSF, and/or PR.

In another aspect, the present disclosure provides methods of immunizing a pig, comprising administering to the pig a vaccine composition provided herein.

In another aspect, the present disclosure provides CSFV vaccine strains, cultured in a cell line selected from the group consisting of ST, PK-15, Marc-145, MDBK, BT, Vero, BHK-21, porcine kidney cell line (IBRS-2), rabbit kidney cell line (RK), and chicken embryo fibroblast cell line, or a primary cell which is porcine kidney primary cells. In another aspect, the present disclosure provides use of these cell lines in culturing a CSFV vaccine strain.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows 360 continuous nucleotides which are absent in the Nsp2 coding sequence of PRRSV TJM strain, but is present in the Nsp2 nucleotide sequence of PRRSV TJ strain.

FIG. 2 shows the 120 amino acid sequence which are absent in the Nsp2 protein as encoded by PRRSV TJM strain, but is present in the Nsp2 protein of PRRSV TJ strain.

FIG. 3 is a schematic drawing showing the 90-nucleotide deletion in the Nsp2 coding sequence of the highly-pathogenic PRRSV strain, and the 90-nucleotide deletion and the 360-nucleotide deletion in an attenuated PRRSV TJM strain.

FIG. 4 shows the discontinuous 90 nucleotide sequence which is absent in the highly-pathogenic PRRSV TJ strain, but is present in the PRRSV VR-2332 strain.

FIG. 5 shows the electrophoresis image of PRRSV TJM vaccine strain (lane 2), the highly-pathogenic PRRSV TJ virulent strain (lane 1), and water (lane 3, as negative control), respectively. M refers to the molecular weight marker.

FIG. 6 shows the electrophoresis image of PRV vaccine strain (lane 1), virulent strain (lane 2), and water (lane 3, as negative control), respectively. M refers to the molecular weight marker.

FIG. 7 shows the changes (%) in CD3+ T cells in test pigs vaccinated with PRRSV TJM single vaccine, CSFV C strain (F16) single vaccine, and combined vaccine, or negative control.

FIG. 8 shows the changes (%) in CD4+ T cells in test pigs vaccinated with PRRSV TJM single vaccine, CSFV C strain (F16) single vaccine, and combined vaccine, or negative control.

FIG. 9 shows the changes (%) in CD8+ T cells in test pigs vaccinated with PRRSV TJM single vaccine, CSFV C strain (F16) single vaccine, and combined vaccine, or negative control.

FIG. 10 shows the changes (%) in CD4+ CD8+ T cells in test pigs vaccinated with PRRSV TJM single vaccine, CSFV C strain (F16) single vaccine, combined vaccine for PRRSV and CSFV, or negative control.

FIG. 11 shows the PRRSV antibody titers (determined by ELISA) in pigs vaccinated with PRRSV TJM single vaccine, combined vaccine for PRRSV TJM and CSFV C strain (F16), or negative control.

FIG. 12 shows the CSFV antibody titers (determined by ELISA) in pigs vaccinated with CSFV C strain (F16) single vaccine, combined vaccine for PRRSV TJM and CSFV C strain (F16), or negative control.

FIG. 13 shows the rectal temperatures of pigs after vaccination with PRRSV TJM single vaccine, CSFV C strain (F16) single vaccine, combined vaccine for PRRSV TJM and CSFV C strain (F16), or negative controls.

FIG. 14 shows the rectal temperatures of pigs after challenge with PRRSV virulent viruses, the pigs were vaccinated with PRRSV TJM single vaccine, combined vaccine for PRRSV TJM and CSFV C strain (F16), or negative control.

FIG. 15 shows the rectal temperatures of pigs after challenge with CSFV virulent viruses, the pigs were vaccinated with CSFV C strain (F16) single vaccine, combined vaccine for PRRSV TJM and CSFV C strain (F16), or negative control.

FIG. 16 shows the clinical symptom scores of pigs after challenge with PRRSV virulent viruses, the pigs were vaccinated with PRRSV TJM single vaccine, combined vaccine for PRRSV TJM and CSFV C strain (F16), or negative control.

FIG. 17 shows the clinical symptom scores of pigs after challenge with CSFV virulent viruses, the pigs were vaccinated with CSFV C strain (F16) single vaccine, combined vaccine for PRRSV TJM and CSFV C strain (F16), or negative control.

FIG. 18 shows the changes (%) in CD3+ T cells in pigs after challenge with PRRSV virulent viruses, the pigs were vaccinated with PRRSV TJM single vaccine, combined vaccine for PRRSV TJM and CSFV C strain (F16), or negative control.

FIG. 19 shows the changes (%) in CD4+ T cells after challenge with PRRSV virulent viruses.

FIG. 20 shows the changes (%) in CD8+ T cells after challenge with PRRSV virulent viruses.

FIG. 21 shows the changes (%) in CD4+ CD8+ T cells after challenge with PRRSV virulent viruses.

FIG. 22 shows the changes (%) in CD3+ T cells after challenge with CSFV virulent viruses, the pigs were vaccinated with CSFV C strain (F16) single vaccine, combined vaccine for PRRSV and CSFV, or negative control.

FIG. 23 shows the changes (%) in CD4+ T cells after challenge with CSFV virulent viruses.

FIG. 24 shows the changes (%) in CD8+ T cells after challenge with CSFV virulent viruses.

FIG. 25 shows the changes (%) in CD4+ CD8+ T cells after challenge with CSFV virulent viruses.

FIG. 26 shows the titer of anti-PRV neutralizing antibody after the vaccination with PRRSV and PRV. Group I was inoculated with PRRSV TJM single vaccine and PRV Bartha K61 single vaccine sequentially, group II was inoculated with 2-combo live vaccine, group III was inoculated with PRV Bartha K61 single vaccine, group IV was only inoculated with sterile PBS.

FIG. 27 shows the virus titers of CSFV C strain (F16) in the CSFV single vaccine and in the 2-combo vaccine (PRRSV and CSFV) after storage at 37.degree. C. for 14 days. 200904, 200905 and 200906 represent three batches of 2-combo vaccine, and 200901, 200902 and 200903 represent three batches of PRRSV TJM single vaccine.

FIG. 28 shows the virus titers of PRRSV TJM strain in the PRRSV single vaccine and in the 2-combo vaccine (PRRSV and CSFV) after storage at 37.degree. C. for 14 days. 200904, 200905 and 200906 represent three batches of 2-combo vaccine, and 200907, 200908 and 200909 represent three batches of CSFV C strain (F16).

FIG. 29 shows the virus titers of CSFV C strain (F16) in the CSFV single vaccine and in the 2-combo vaccine (PRRSV and CSFV) after storage at 2-8.degree. C. for 18 months. 200904, 200905 and 200906 represent three batches of 2-combo vaccine, and 200901, 200902 and 200903 represent three batches of PRRSV TJM single vaccine.

FIG. 30 shows the virus titers of PRRSV TJM strain in the PRRSV single vaccine and in the 2-combo vaccine (PRRSV and CSFV) after storage at 2-8.degree. C. for 18 months. 200904, 200905 and 200906 represent three batches of 2-combo vaccine, and 200907, 200908 and 200909 represent three batches of CSFV C strain (F16).

FIG. 31 shows the virus titers of PRRSV TJM strain in the 2-combo vaccine (PRRSV and PRV) after storage at 2-8.degree. C. for 24 months. SD001, SD002 and SD003 represent three different batches of 2-combo live vaccine, respectively.

FIG. 32 shows the virus titers of PRV Bartha K61 strain in the 2-combo vaccine (PRRSV and PRV) after storage at 2-8.degree. C. for 24 months. SD001, SD002 and SD003 represent three different batches of 2-combo live vaccine, respectively.

FIG. 33 shows the virus titers of PRRSV TJM strain in the 2-combo vaccine (PRRSV and PRV) after storage at 37.degree. C. for 14 days. SD001, SD002 and SD003 represent three different batches of 2-combo live vaccine, respectively.

FIG. 34 shows the virus titers of PRV Bartha K61 strain in the 2-combo vaccine (PRRSV and PRV) after storage at 37.degree. C. for 14 days. SD001, SD002 and SD003 represent three different batches of 2-combo live vaccine, respectively.

FIG. 35 shows the virus titers of PRRSV TJM strain in the 3-combo live vaccine (PRRSV TJM+CSFV C strain (F16)+PRV Bartha K61) after storage 2-8.degree. C. for 18 months. 031-01, 031-02 and 031-03 represent three batches of 3-combo live vaccine, and 031-04, 031-05 and 031-06 represent three batches of PRRSV TJM single vaccine.

FIG. 36 shows the virus titers of CSFV C strain (F16) strain in the 3-combo live vaccine (PRRSV TJM+CSFV C strain (F16)+PRV Bartha K61) after storage 2-8.degree. C. for 18 months. 031-01, 031-02 and 031-03 represent three batches of 3-combo live vaccine, and 031-07, 031-08 and 031-09 represent three batches of CSFV C strain (F16) single vaccine.

FIG. 37 shows the virus titers of PRV Bartha K61 strain in the 3-combo live vaccine (PRRSV TJM+CSFV C strain (F16)+PRV Bartha K61) after storage 2-8.degree. C. for 18 months. 031-01, 031-02 and 031-03 represent three batches of 3-combo live vaccine, and 031-10, 031-11 and 031-12 represent three batches of PRV Bartha K61 single vaccine.

FIG. 38 shows the virus titers of PRRSV TJM strain in the 3-combo live vaccine (PRRSV TJM+CSFV C strain (F16)+PRV Bartha K61) after storage 37.degree. C. for 14 days. 031-01, 031-02 and 031-03 represent three batches of 3-combo live vaccine, and 031-04, 031-05 and 031-06 represent three batches of PRRSV TJM single vaccine.

FIG. 39 shows the virus titers of CSFV C strain (F16) in the 3-combo live vaccine (PRRSV TJM+CSFV C strain (F16)+PRV Bartha K61) after storage 37.degree. C. for 14 days. 031-01, 031-02 and 031-03 represent three batches of 3-combo live vaccine, and 031-07, 031-08 and 031-09 represent three batches of CSFV C strain (F16) single vaccine.

FIG. 40 shows the virus titers of PRV Bartha K61 strain in the 3-combo live vaccine (PRRSV TJM+CSFV C strain (F16)+PRV Bartha K61) after storage 37.degree. C. for 14 days. 031-01, 031-02 and 031-03 represent three batches of 3-combo live vaccine, and 031-10, 031-11 and 031-12 represent three batches of PRV Bartha K61 single vaccine.

DETAILED DESCRIPTION OF THE INVENTION

The following description is merely intended to illustrate various embodiments of the present disclosure. As such, the specific modifications discussed are not intended to be limiting. It will be apparent to one skilled in the art that various equivalents, changes, and modifications may be made without departing from the spirit or scope of the subject matters presented herein, and it is understood that such equivalent embodiments are to be included herein. All publications, patents or patent applications cited herein are incorporated by reference to their entirety.

One aspect of the present disclosure relates to vaccine compositions, comprising a Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) vaccine and a second porcine virus vaccine, wherein the PRRSV vaccine and the second vaccine are substantially free from immuno-inhibition against each other.

PRRSV is a positive-strand RNA virus, for which two genotypes are currently identified: European genotype and American genotype. The genome of PRRSV contains multiple open reading frames, in which the first open reading frame (ORF1a and ORF1b) contains 80% of the sequence in the PRRSV genome, and encodes the RNA replicase which is required for PRRSV replication (Straw et al, Diseases of Swine, 9TH edition, chapter 24 (2006)). ORF1a and ORF1b are translated into a poly-protein, which is cleaved by a protease domain contained therein into several non-structural proteins, including Nsp1-Nsp12 (see, eg, Vries et al, Seminars in Virology, 8: 33-47 (1997); Allende et al, Journal of General Virology, 80: 307-315 (1999)).

The PRRSV vaccine and the second porcine virus vaccine are substantially free from immuno-inhibition against each other.

The term "substantially free from immuno-inhibition" as used herein means that, the combination two or more single vaccines does not lead to substantial reduction in protective immune response in a host to one of the single vaccines or to all of the single vaccines. The term "substantial reduction," as used herein, refers to .gtoreq.20% reduction (e.g. .gtoreq.30%, .gtoreq.40%, .gtoreq.50%, or .gtoreq.60% reduction).

In certain embodiments, the combination of two or more single vaccines is capable of eliciting protective immune response to each of the single vaccines at a level comparable to that elicited by a single vaccine. For example, the combined PRRSV vaccine and the second porcine virus vaccine can elicit immune response to PRRSV which is at a level comparable to the immune response elicited by the PRRSV single vaccine, and/or can elicit immune response to the second porcine virus vaccine which is at a level comparable to the immune response elicited by the second porcine virus single vaccine.

The protective immune response typically includes humoral, cellular and/or mucosal immune responses, and can be characterized using methods known in the art. Humoral immune response is generated by production of antibodies (e.g. IgG) in the serum against the antigen. The antibody titers can be readily measured using assays such as ELISA (enzyme linked immunosorbent assay). For example, the virus antigen can be coated on a solid support, and then contacted with a sample suspected of containing the antibody, followed by determination of the formation of antigen-antibody complex. Cellular immune response is usually resulted from generation of cytotoxic T lymphocytes, and can be characterized through measurement of certain subpopulations of the T cells, such as CD3+ T cells, CD4+ T cells, CD8+ T cells, and CD4+CD8+ T cells, using methods such as flow cytometry. Briefly, the T cells are stained with antibodies against certain surface markers, and were sorted and quantified as different sub-populations according to the presence of the surface markers. Mucosal immune response is typically resulted from secretory IgA generated on the mucosal surfaces.

In certain embodiments, the PRRSV vaccine and the second porcine virus vaccine, when administered as a combined vaccine composition, do not substantially reduce antibody production in a host in response to the PRRSV vaccine and/or the second porcine virus vaccine.

In certain embodiments, the PRRSV vaccine and the second porcine virus vaccine, when administered as a combined vaccine composition, do not substantially reduce levels of CD3+ T cells, CD4+ T cells, CD8+ T cells, and/or CD4+CD8+ T cells in a host in response to the PRRSV vaccine and/or the second porcine virus vaccine.

In certain embodiments, the PRRSV vaccine comprises an attenuated PRRSV. In the present disclosure, "attenuated PRRSV" as used herein refers to a PRRSV that can infect a host but do not cause porcine reproductive and respiratory syndrome, or having less and/or milder symptoms. Attenuated PRRSV includes live attenuated PRRSV and its inactivated products. "Porcine reproductive and respiratory syndrome" (PRRS) as used herein refers to a series of physiological and pathological symptoms after infection of a naturally-occurring PRRSV. The symptoms include, without limitation, fever, drowsiness, anorexia, lassitude, dyspnea, cough, breeding disorder in sows, and slow growth or death in piglets, among others.

In certain embodiments, the attenuated PRRSV comprises an Nsp2 nucleotide encoded by a DNA sequence which, when compared with SEQ ID NO: 4, lacks a nucleotide fragment comprising at least 50 contiguous nucleotides, wherein the fragment is at least about 80% homologous to an equal length portion of SEQ ID NO: 8.

The term "encoded by a DNA sequence" as used herein refers to a DNA sequence that can be transcribed into a corresponding RNA sequence. A single stranded RNA virus, such as PRRSV and CSFV, has a genome which is composed of a singe strand RNA molecule that can be encoded by a DNA molecule based on Watson Crick base pairing. Such DNA molecule, when transcribed, can produce a positive-strand RNA molecule that is the identical to the RNA sequence in the virus genome.

Without being bound to theory, but it is contemplated that the absence of such nucleotide fragment in Nsp2 sequence within the portion homologous to SEQ ID NO: 8 can reduce the virulence as well as the immuno-inhibition potential of PRRSV, by, for example, producing a non-functional or less-functional Nsp2 protein, and/or negatively affecting the expression or function of other PRRSV proteins, and/or negatively affecting the life cycle of the PRRSV.

The absent fragment can be of any suitable length, as long as it can reduce the virulence as well as the immuno-inhibition of PRRSV, to the extent that is sufficient to abolish PRRSV virulence and to induce protective immunity against PRRSV without impairing immunity against other co-infected virus or vaccines. For example, the absent DNA fragment can comprise at least 100, at least 120, at least 150, at least 180, at least 200, at least 210, at least 220, at least 230, at least 240, at least 250, at least 260, at least 270, at least 280, at least 290, at least 300, at least 310, at least 320, at least 330, at least 340, at least 350, or at least 360 contiguous nucleotides. The length of the absent nucleotide fragment can also be within a range defined by any of the two values as provided above, as if these ranges have been explicitly listed herein. In certain embodiments, the absent nucleotide fragment comprises about 300 contiguous nucleotides, about 310, about 320, about 330, about 340, about 350, or about 360 contiguous nucleotides.

People of ordinary skill in the art can readily prepare recombinant viruses having various deletions in Nsp2 nucleotide sequence within the portion homologous to SEQ ID NO: 8, and test these recombinant viruses for their viability, virulence, and immuno-inhibition potential, using methods known in the art and methods provided in the present disclosure. For example, with the respect to producing and testing virulence of recombinant PRRSV containing deletions in Nsp2, methods have been described in Kim, Dal-Young et al, Virus Genes, 38: 118-128 (2009). With respect to testing immuno-inhibition of the recombinant PRRSV, methods have been described in Suradhat, S. et al, Vaccine, 24: 2634-3642 (2006), and also in Examples of the present disclosure. By deleting a fragment within the portion homologous to SEQ ID NO: 8 (e.g. deleting the 1.sup.st nucleotide through the 50.sup.th nucleotide in the portion, the 2.sup.nd through the 60.sup.th nucleotide, the 5.sup.th through the 100.sup.th nucleotide, etc.), one can prepare recombinant PRRSV comprising an Nsp2 nucleotide of interest, and further test the viable recombinant PRRSV strains for their abilities in forming cytopathic plaques, such that attenuated recombinant PRRSV strains can be selected and further tested in pigs for immuno-inhibition potential with respect to a second porcine virus vaccine.

In certain embodiments, the absent DNA fragment is at least about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or 100% homologous to an equal length portion of SEQ ID NO: 8. In certain embodiments, the absent DNA fragment comprises SEQ ID NO: 8. In certain embodiments, the absent DNA fragment is SEQ ID NO: 8 (see FIG. 1).

In certain embodiments, the attenuated PRRSV comprises an Nsp2 nucleotide encoding for a Nsp2 protein sequence which, when compared with SEQ ID NO: 11, lacks a peptide fragment comprising at least 20 contiguous amino acids, wherein the peptide fragment is at least about 80% homologous to an equal length portion of SEQ ID NO: 9.

The term "encoding for" as used herein means that an RNA sequence that can be translated to a corresponding amino acid sequence in accordance to the genetic codons.

Without being bound to theory, but it is contemplated that Nsp2 protein lacking such peptide fragment is less-functional or non-functional, thus impairing the virulence of the PRRSV and also reduce the immuno-inhibition on a second porcine virus vaccine.

In certain embodiments, the absent peptide fragment comprises at least 30, at least 40, at least 50, at least 60, at least 70, at least 75, at least 80, at least 85, at least 90, at least 95, at least 100, at least 105, at least 110, at least 115, or at least 120 contiguous amino acids. In certain embodiments, the absent peptide fragment is at least about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or 100% homologous to an equal length portion of SEQ ID NO: 9. In certain embodiments, the absent peptide fragment comprises SEQ ID NO: 9. In certain embodiments, the absent peptide fragment is SEQ ID NO: 9 (see FIG. 2).

The absence of the peptide fragment in Nsp2 protein can be determined through the Nsp2 nucleotide sequence. For example, the Nsp2 nucleotide can be sequenced and translated to amino acid sequence, followed by alignment with SEQ ID NO: 11 to identify the absent peptide sequence.

"Homology" or "homologous" as used herein refers to the similarity between two amino acid sequences or two nucleotide sequences. The homology between the amino acid sequences or nucleotide sequences can be calculated using any suitable methods known in the art, for example, the candidate amino acid (nucleotide) sequence can be aligned with a reference amino acid (nucleotide) sequence, introducing gaps if necessary, to achieve the maximum number of identical amino acid residues (nucleotides) between the aligned sequences, on which basis the percentage of the identical amino acid residues (nucleotides) between the two amino acid (nucleotide) sequences can be calculated. Alignment of the amino acid (or nucleotide) sequences and calculation of their homology can be achieved using the software known in the art, for example without limitation, BLAST program see, e.g., Altschul S. F. et al, J. Mol. Biol., 215:403-410 (1990); Stephen F. et al, Nucleic Acids Res., 25:3389-3402 (1997)), ClustalW2 software see, e.g., Higgins D. G. et al, Methods in Enzymology, 266:383-402 (1996); Larkin M. A. et al, Bioinformatics (Oxford, England), 23(21): 2947-8 (2007)); and TCoffee software, etc see, e.g., Poirot O. et al, Nucleic Acids Res., 31(13): 3503-6 (2003); Notredame C. et al, J. Mol. Boil., 302(1): 205-17 (2000)). When software is used to align sequences, default parameters provided by software can be used or adjusted according to the actual situation, and these are within the scope of knowledge of an ordinary artisan in the art.

In certain embodiments, the attenuated PRRSV is attenuated from a highly-pathogenic PRRSV.

The term "highly-pathogenic PRRSV" refers to a PRRSV comprising an Nsp2 nucleotide encoded by a DNA sequence which, when compared with SEQ ID NO: 5, lacks discontinuous 90 nucleotides within the portion of SEQ ID NO: 6 (i.e. the fragment from the 1440th to the 1680th nucleotide of SEQ ID NO: 5). PRRSV isolates lacking such 90 discontinuous nucleotides (see FIG. 3) are found to have higher pathogenicity than PRRSV VR-2332 strain (see, e.g. Tian et al, PLoS ONE 2(6): e526, (2007) doi:10.1371). In certain embodiments, the discontinuous 90 nucleotides include the "TTT" from the 1440 to the 1442 nucleotide of SEQ ID NO: 5 and the sequence as shown in SEQ ID NO: 7 (see, for example, FIG. 4).

In certain embodiments, the highly-pathogenic PRRSV comprise an Nsp2 nucleotide encoded by a sequence comprising a nucleotide sequence of SED ID NO: 4 (i.e., the Nsp2 nucleotide sequence of PRRSV TJ strain). In certain embodiments, the highly-pathogenic PRRSV is PRRSV TJ strain, whose genome is encoded by a sequence having a GenBank Accession number of EU860248.

In certain embodiments, the attenuated PRRSV is attenuated from the highly-pathogenic PRRSV, and comprises an Nsp2 nucleotide sequence lacking discontinuous 90 nucleotides when compared with SEQ ID NO: 5, wherein the discontinuous 90 nucleotides are within SEQ ID NO: 6.

In certain embodiments, the Nsp2 nucleotide of the attenuated PRRSV is encoded by a sequence having at least 90% homology to SEQ ID NO: 2 (i.e. the sequence encoding Nsp2 nucleotide of PRRSV TJM strain). In certain embodiments, the Nsp2 nucleotide is encoded by a sequence comprising SEQ ID NO: 2.

In certain embodiments, the attenuated PRRSV further comprises an Nsp1 nucleotide sequence, which is encoded by a sequence having at least 90% homology to SEQ ID NO: 1 (i.e. the sequence encoding Nsp1 nucleotide of PRRSV TJM strain). In certain embodiments, the attenuated PRRSV comprises an Nsp1 nucleotide sequence encoded by SEQ ID NO: 1, and an Nsp2 nucleotide sequence encoded by SEQ ID NO: 2.

In certain embodiments, the attenuated PRRSV comprises a PRRSV nucleotide sequence encoded by a sequence having at least 90% homology to SEQ ID NO: 3 (i.e. the sequence encoding genome of PRRSV TJM strain). In certain embodiments, the attenuated PRRSV comprises a PRRSV nucleotide sequence encoded by SEQ ID NO: 3. In certain embodiments, the attenuated PRRSV has a microorganism deposit number of CGMCC No.: 3121 (such attenuated PRRSV strain is also referred to herein as PRRSV TJM strain).

The PRRSV vaccine provided herein is substantially free from immuno-inhibition against a second porcine virus vaccine. In certain embodiments, the second porcine virus vaccine is selected from Classical Swine Fever Virus (CSFV) vaccine and Pseudorabies Virus (PRV) vaccine.

Classical Swine Fever (CSF) is a highly contagious and lethal swine infectious disease caused by Classical Swine Fever Virus (CSFV). World Organization for Animal Health (OIE) has included the disease in the OIE disease list as a disease required by law to be reported. In China, classical swine fever is one of the major infectious diseases, and is listed as type I animal disease in "Category of Type I, II and III Animal Diseases." The outbreak and prevalence of the CSF has led to the great economic loss in pig industry in China and worldwide.

Classical swine fever virus (CSFV) is classified as a member of the Pestivirus genus within the Flaviviridae family of viruses. CSFV is an enveloped positive-strand RNA virus. The virus has a genome of 12.5 kb in its full length, which comprises only one large open reading frame (ORF) that encodes a poly-protein containing approximately 4000 amino acids and with a molecular weight of about 438 kD. The poly-protein is further processed into 12 mature proteins by the viral and host proteases. All of the structural and non-structural proteins of CSFV are encoded by this large open reading frame.

An important tool to control the classical swine fever is vaccines, including inactivated vaccines and attenuated vaccines. Preparation of inactivated CSFV vaccines reached its peak in 1950-1960's, during which period formalin and crystal violet inactivated CSFV vaccines were widely used. However, they were gradually replaced by the attenuated CSFV vaccines due to their disadvantages in large dosage, short duration of immunity, slow generation of immune responses and high costs.

In certain embodiments, the CSFV vaccine is an attenuated CSFV vaccine. CSFV attenuated vaccine strains can be produced by attenuation of CSFV field strains. Reports in other countries showed that, different methods can be used to adapt CSF viruses in rabbits and to produce attenuated mutant strains. For example, three attenuated vaccine strains are widely accepted as safe and effective yet without residual pathogenicity: 1) Chinese lapinized vaccine strain (see, e.g. Qiu, H. J. et al, Scientia Agricultura Sinica, 38(8): 1675-1685 (2005)); 2) Japanese GPE(-) cell attenuated vaccine strain (see, e.g. Liu, C. et al, Chinese Journal of Animal Husbandry and Veterinary Medicine, Vol. 10, pp. 50-51 (2004)); and 3) French "Thiveosal" cold attenuated vaccine strain (see, e.g. Zhu, L. Q. et al, Chinese Veterinary Journal, 39 (2):

In certain embodiments, the attenuated CSFV vaccine is Chinese lapinized vaccine strain (C strain). The genome sequence of CSFV C strain is shown in SEQ ID NO: 10. The Chinese CSF lapinized vaccine (also called C strain), developed by Chinese scientists, has been widely used in China since 1957, and has been introduced to many other countries, where classical swine fever was brought under control or eliminated. This vaccine has been recognized as one of the most useful CSFV vaccine strains worldwide.

The CSF lapinized vaccine (C strain) can be classified according to the different methods of preparation. The first method involves preparing the vaccine in rabbits. A rabbit is inoculated with CSFV, and the lymph node, spleen or tissue is collected from the rabbit to prepare CSFV vaccine of spleen and lymph tissue origin, or CSFV vaccine of rabbit origin. This method can effectively prevent contamination of exogenous virus and ensure genetic stability of the virus. However, a lot of rabbits are required yet the quality is hard to control, and the manufacturing cost is relatively high. The second method involves using cattle or sheep primary cells or a swine cell line to produce the vaccine, i.e. CSFV vaccine of cell origin. For example, CSFV vaccine of cell origin can be prepared by passing the CSF lapinized virus (spleen origin) in cells, and performing two rounds of clonal purification by serial dilutions. This method does not require using a lot of animals. In certain embodiments, the CSFV C strain is CSFV C strain of spleen and lymph tissue origin. In certain embodiments, the CSFV C strain is CSFV C strain of cell origin, which can be derived from primary cells or a cell line.

In certain embodiments, the attenuated CSFV is encoded by a sequence having at least 80% homology to SEQ ID NO: 10 (i.e. a sequence encoding the genome of CSFV C strain). In certain embodiments, the attenuated CSFV is encoded by SEQ ID NO: 10.

In certain embodiments, the attenuated CSFV has a microorganism deposit number of CGMCC No.: 3891 (such attenuated CSFV strain is also referred to herein as CSFV C strain or F16 or CSFV C strain (F16)). CSFV C strain (F16) is CSFV C strain of cell origin.

In certain embodiments, the second porcine virus vaccine is Pseudorabies Virus (PRV) vaccine.

PRV belongs to the family of Herpesvirdae and subfamily of Alpherpesvirinae. At present, only one serotype of PRV has been identified. The genome of PRV is double-stranded DNA, having a length of about 150 kb. The virus genome is composed of a unique long (UL) region, a unique short (US) region, and terminal repeat sequences flanking the US region and internal repeat sequences. To date, 65 genes have been located in the PRV genome and most of them have been functional characterized. 56 genes have been located in the UL region, including glycoproteins such as gB, gC, gH, gK, gL, gM, gN, thymidine kinase (TK), alkaline nuclease (AN), ribonucleotide reductase (RR), DNA polymerase (POL), DBP gene, MCP gene, ICP18.5 gene and early protein 0 (EP0) and etc. The US region has been fully sequenced, in which 7 genes have been located, including: glycoprotein gD, gE, gG, gI, and protein kinase (PK) gene, 11 kd and 28 kd protein gene.

In certain embodiments, the PRV vaccine comprises an attenuated PRV. The term "attenuated PRV vaccine" refers to a PRV that is capable of infecting its host but does not cause Pseudorabies or with reduced or less severe symptoms. The attenuated PRV include live attenuated PRV and its inactivated product thereof "Pseudorabies" refers to a series of physiological and pathological symptoms caused by infection of wild type PRV. Such symptoms include, without limitation, miscarriage, stillbirth, weak foetus, mummified foetus, fever, low appetite, neurological symptoms, paralysis, system failure and even death.

In certain embodiments, the attenuated PRV comprises a sequence having at least 80% homology to a sequence having an NCBI reference number of NC 006151, for example, having at least 85%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% homology.

In certain embodiments, the attenuated PRV has one or more inactivated genes related to pathogenicity. An "inactivated" gene refers to a gene whose function is reduced or abolished due to lack or deletion of complete or partial sequences, or due to insertions or mutations in the gene. Examples of genes related to PRV pathogenicity include, without limitation, TK (for example, NCBI Gene ID: 2952559), PK (for example, NCBI Gene ID: 2952530 or 2952561), RR (for example, NCBI Gene ID: 2952535 or 2952536), dUTPase (for example, NCBI Gene ID: 2952537), gG (for example, NCBI Gene ID: 2952520), gC (for example, NCBI Gene ID: 2952505), gE (for example, NCBI Gene ID: 2952517), gD (for example, NCBI Gene ID: 2952521) and gI (for example, NCBI Gene ID: 2952516).

In certain embodiments, the attenuated PRV has one or more inactivated genes selected from the group consisting of TK, PK, RR, dUTPase, gG, gC, gE, gD and gI. In certain embodiments, the attenuated PRV has an inactivated gE gene. In certain embodiments, only gE gene is inactivated in the attenuated PRV. In certain embodiments, the attenuated PRV has an inactivated gE gene, and further has one or more inactivated genes related to pathogenicity, for example, TK, PK, RR, dUTPase, gG, gC, gD and/or gI.

The attenuated PRV vaccine can be obtained using methods known in the art. For example, an isolate of PRV wild type strain can be attenuated by passaging the virus in non-porcine cells or in egg embryos, or by culturing under an elevated temperature and/or in the presence of a mutagen. Many attenuated PRV vaccines are known in the art, for example, Bartha K61 strain (see, for example, Bartha, A. Experiments to reduce the virulence of Aujeszky's virus. Magyar allatorvosok lapja 16, 42-45 (1961)), BUK strain, NIA4 strain, Alfort strain, and VGNKI strain etc. These attenuated PRV vaccines can be used in the present disclosure. For example, the wild type or attenuated PRV strain may further be modified, such that one or more target genes related to pathogenicity are inactived yet the virus is still capable of replication. Many attenuated PRV vaccines obtained by genetic engineering are known in the art, for example, PRV-BUK-d13 strain (see, for example, Kit S. et al, Am. J. Vet. Res., 1985, 46 (6): 1359-1367), PRV dlgC/dlTK strain (see, for example, Kit S. et al, Am. J. Vet. Res., 1987, 48 (5): 780-793), S--PRV-002 (see, for example, U.S. Pat. No. 4,514,497), PRV783 strain (see, for example, Van Oirschot J T et al, Am. J. Vet. Res., 1984, 45 (10): 2099-2103), EL-001, and PRV376 etc.

In certain embodiments, the attenuated PRV lacks gE gene. In certain embodiments, the attenuated PRV has a microorganism deposit number of CGMCC No.: 5076 (such attenuated PRV strain is also referred to as PRV Bartha K61 strain herein).

In certain embodiments, the attenuated PRV further comprises one or more inactivated genes that do not affect viral replication or host infection. In certain embodiments, the attenuated PRV further comprises one or more heterogeneous genes that are not present in PRV genome. The inserted heterogeneous genes are useful in detection and/or diagnosis of the vaccines.

In certain embodiments, the vaccine composition further comprises a third porcine vaccine, wherein the PRRSV vaccine, the second porcine virus vaccine and the third porcine virus vaccine are substantially free from immuno-inhibition against each other. In certain embodiments, the third porcine vaccine can be selected from a CSFV vaccine and a PRV vaccine, provided that the second vaccine is different from the third vaccine.

In certain embodiments, the vaccine compositions comprise a PRRSV vaccine, a CSFV vaccine and a PRV vaccine, wherein the PRRSV vaccine, the CSFV vaccine and the PRV vaccine are substantially free from immuno-inhibition against each other. The three vaccines, when combined in a vaccine composition, do not substantially reduce antibody production and/or T cell subpopulation levels in a host in response to the PRRSV vaccine, the CSFV vaccine and/or the PRV vaccine. In certain embodiments, the PRRSV vaccine comprises PRRSV TJM strain. The CSFV vaccine comprises any of the attenuated CSFV provided herein, including but not limited to, CSFV C strain. The PRV vaccine comprises any of the attenuated PRV strain provided herein, for example but not limited to, PRV Bartha K61 strain.

In certain embodiments, the present disclosure provides a vaccine composition, comprising PRRSV TJM strain having a microorganism deposit No. of CGMCC NO. 3121, and CSFV C strain. In certain embodiments, the CSFV C strain is CSFV F16 having a microorganism deposit No. of CGMCC NO. 3891. PRRSV TJM strain and CSFV C strain (F16) do not show any immuno-inhibition or immune suppression against each other. Both vaccine strains have good safety, immunogenicity and specificity, and can provide effective protection against both the highly-pathogenic porcine reproductive and respiratory syndrome and classical swine fever, which are two of the major epidemics in pig herds.

In certain embodiments, the present disclosure provides a vaccine composition, comprising PRRSV TJM strain having a microorganism deposit No. of CGMCC NO. 3121, and PRV Bartha K61 strain with microorganism deposit No. of CGMCC NO. 5076. PRRSV TJM strain and PRV Bartha K61 strain do not show any immuno-inhibition or immune suppression between each other. Both vaccine strains have good safety, immunogenicity and specificity, and can provide effective protection against both the highly-pathogenic porcine reproductive and respiratory syndrome and pseudorabies, which are two of the major epidemics in pig herds.

In certain embodiments, the present disclosure provides a vaccine composition, comprising PRRSV TJM strain, CSFV C strain (F16) and PRV Bartha K61 strain. PRRSV TJM strain, CSFV C strain (F16) and PRV Bartha K61 strain do not show any immuno-inhibition or immune suppression among each other. The three vaccine strains have good safety, immunogenicity and specificity, and can provide effective protection against the highly-pathogenic porcine reproductive and respiratory syndrome, classical swine fever and pseudorabies, which are three of the major epidemics in pig herds.

The detailed deposit information of PRRSV TJM strain is as follows: Microorganism Deposit No.: CGMCC No. 3121; Taxonomic Name: Porcine Reproductive and Respiratory Syndrome Virus; Deposit Address: Institute of Microbiology, Chinese Academy of Sciences, NO. 1 West Beichen Road, Chaoyang District, Beijing, China; Deposit Unit: China General Microbiological Culture Collection Center; and Deposit Date: Jun. 15, 2009.

The detailed deposit information of CSFV C strain (F16) is as follows: Microorganism Deposit No.: CGMCC No. 3891; Taxonomic Name; Classical Swine Fever Virus; Deposit Address: Institute of Microbiology, Chinese Academy of Sciences, NO. 1 West Beichen Road, Chaoyang District, Beijing, China; Deposit Unit: China General Microbiological Culture Collection Center; and Deposit Date: May 27, 2010.

The detailed deposit information of PRV Bartha K61 strain is as follows: Microorganism Deposit No.: CGMCC No. 5076; Taxonomic Name: Pseudorabies Virus; Deposit Address: Institute of Microbiology, Chinese Academy of Sciences, NO. 1 West Beichen Road, Chaoyang District, Beijing, China; Deposit Unit: China General Microbiological Culture Collection Center; and Deposit Date: Jul. 21, 2011.

In certain embodiments, the vaccine composition provided herein comprises an immunologically effective amount of PRRSV vaccine, CSFV vaccine and/or PRV vaccine. The term "immunologically effective amount" as used herein, refers to an amount of a vaccine that is sufficient to induce a protective immune response in the host against the intended antigen or pathogen. For example, an immunologically effective amount may be sufficient to reduce or delay the onset of one or more symptoms of the infection, reduce morbidity and/or mortality of the infected host, induce a sufficient level of antibodies against the pathogen, increase levels of T cell sub-populations, and any combinations thereof. Characterization and/or quantification of the protective immune response can be carried out using methods known in the art, for example, by measuring antibody titers against the pathogen, and/or amount of T cell subpopulations, as described above, or by observing for clinical manifestations of the vaccinated pigs after virulent virus challenge.

The immunologically effective amount of a virus vaccine can be characterized in virus titer, for example, in 50% tissue culture infective dose (TCID.sub.50). In certain embodiments, the immunologically effective amount of the PRRSV vaccine is at least 10.sup.3.0 TCID.sub.50, 10.sup.3.5 TCID.sub.50, 10.sup.4.0 TCID.sub.50, 10.sup.4.5 TCID.sub.50, 10.sup.5.0 TCID.sub.50, or 10.sup.5.5 TCID.sub.50. In certain embodiments, the immunologically effective amount of the PRRSV vaccine is at least 10.sup.4.5 TCID.sub.50, at least 10.sup.5.0 TCID.sub.50 or at least 10.sup.5.5 TCID.sub.50. In certain embodiments, the vaccine compositions provided herein comprises about 10.sup.4.5 TCID.sub.50 to about 10.sup.6.0 TCID.sub.50, or about 10.sup.5.0 TCID.sub.50 to about 10.sup.6.0 TCID.sub.50 of the PRRSV vaccine.

In certain embodiments, the immunologically effective amount of the CSFV vaccine is at least 10.sup.0.5 FA-TCID.sub.50 (fluorescent antibody--TCID.sub.50), 10.sup.1.0 FA-TCID.sub.50, 10.sup.1.5 FA-TCID.sub.50, 10.sup.2.0 FA-TCID.sub.50, 10.sup.2.5 FA-TCID.sub.50, 10.sup.3.0 FA-TCID.sub.50, 10.sup.3.5 FA-TCID.sub.50, 10.sup.4.0 FA-TCID.sub.50, 10.sup.4.5 FA-TCID.sub.50, or 10.sup.5.0 FA-TCID.sub.50. In certain embodiments, the immunologically effective amount of the CSFV vaccine is at least 10.sup.4.0 FA-TCID.sub.50/ml. In certain embodiments, the vaccine compositions provided herein comprises about 10.sup.0.5 FA-TCID.sub.50 to about 10.sup.5.0 FA-TCID.sub.50, or about 10.sup.4.0 FA-TCID.sub.50 to about 10.sup.5.0 FA-TCID.sub.50 of the CSFV vaccine. The term "FA-TCID50" refers to a TCID.sub.50 value determined by a method based on fluorescent antibody.

In certain embodiments, the immunologically effective amount of the CSFV vaccine is at least 2.5 RID, 3 RID, 5 RID, 10 RID, 30 RID, 100 RID, 150 RID, 300 RID, 750 RID, 1000 RID, 3000 RID, or 7500 RID.

In certain embodiments, the immunologically effective amount of the PRV vaccine is at least 10.sup.3.0 TCID.sub.50, 10.sup.3.5 TCID.sub.50, 10.sup.4.0 TCID.sub.50, 10.sup.4.5 TCID.sub.50, 10.sup.5.0 TCID.sub.50, 10.sup.5.5 TCID.sub.50 or 10.sup.6.0 TCID.sub.50. In certain embodiments, the immunologically effective amount of the PRV vaccine is at least 10.sup.5.5 TCID.sub.50, or at least 10.sup.6.0 TCID.sub.50. In certain embodiments, the vaccine compositions provided herein comprises about 10.sup.5.0 TCID.sub.50 to about 10.sup.6.5 TCID.sub.50, or about 10.sup.5.5 TCID.sub.50 to about 10.sup.6.5 TCID.sub.50 of the PRV vaccine.

The TCID.sub.50 of a virus vaccine can be determined using any suitable methods known in the art. For example, the virus vaccine (PRRSV vaccine and/or PRV vaccine) can be prepared as a virus solution, and 10-fold serial dilutions of the virus solution can be prepared and inoculated to a 96-well culture plate seeded with susceptible cells. Virus solutions of each dilution can be inoculated in 8 wells at 100 ul/well. The plates can be placed in an incubator at 37.degree. C., with 5% CO.sub.2, and cultured for 4-5 days. The cells are observed for cytopathic effects, and TCID.sub.50 is calculated as the virus concentration at which 50% of the tissue culture shows cytopathic effects. A detailed description of the method can be found at Reed L J, Muench H, A simple method of estimating fifty percent end points. Am J Hyg 1938; 27:493-97.

CSFV is a virus that does not cause obvious cytopathic effects, and the TCID.sub.50 is therefore determined by immunofluorescent method, or with rabbit infection study. In certain embodiments, the FA-TCID.sub.50 for the CSFV vaccine is determined by an immunofluorescent method. Briefly, the CSFV vaccine strain is prepared as a solution containing 1 dose/ml, and 10-fold serial dilutions are prepared with DMEM culture medium supplemented with 3.5% serum. Dilutions containing 10.sup.-1, 10.sup.-2, 10.sup.-3, 10.sup.-4, and 10.sup.-5 of original virus samples are inoculated respectively to single layer of BT cells at 0.1 ml/well. After 3-4 days culture, the cells are fixed and contacted with a fluorescent monoclonal antibody of CSFV (for direct immunofluoresenct method). After 45-60 minutes reaction, the cells are observed for presence of fluorescence, which indicates for presence of virus. Alternatively, the fixed cells can be contacted with an unlabelled monoclonal antibody of CSFV (for indirect immunofluoresenct method), and after 45-60 minutes reaction, the cells are reacted with fluorescence-labeled secondary antibody for another 45-60 minutes. The cells are observed for presence of fluorescence which indicates the presence of the virus. FA-TCID50 is calculated in accordance with the Reed-Muench method (see, e.g Reed L J, Muench H, A simple method of estimating fifty percent end points. Am J Hyg 1938; 27:493-97).

In certain embodiments, the amount of the CSFV vaccine is determined by rabbit infectivity dose. Briefly, the CSFV vaccine strain is prepared as a solution containing 1 dose, and is then diluted 7500-fold to prepare the testing sample. 2 rabbits of 1.5-3 kg body weight are each injected with 1 ml testing sample, and body temperature is taken twice each day for the first 48 hours, and once every 6 hours thereafter. The body temperature reactions are monitored and graded according the below criteria: 1) typical fever reaction (++): the latency period is about 48-96 hours, the body temperature significantly rises, in which at least 3 temperatures rise beyond the normal temperature by at least 1.degree. C. and last for 18-36 hours; 2) slightly fever reaction (+): the latency period is about 48-96 hours, the body temperature significantly rises, in which at least 2 temperatures rise beyond the normal temperature by at least 0.5.degree. C. and last for 12-36 hours; 3) suspected fever reaction (.+-.): the latency period is about 48-96 hours, the body temperature fluctuates, the elevated temperature lasts for less than 12 hours, or the latency period is at least 24 hours, and fever reaction is demonstrated within 48 hours, or after 96 to 120 hours; and 4) no fever reaction (-): body temperature is normal. The vaccine is determined as having an amount of 7500 RID, if the two testing rabbits both showed typical fever reaction (++), or one of the rabbits showed typical fever reaction (++) while the other showed slightly fever reaction (+). In case the rabbits showed other reactions that are difficult to characterize, the test can be repeated, but should not be repeated for more than 3 times.

The single virus vaccines can be mixed at a suitable ratio to provide the vaccine compositions described herein. For example, a single virus vaccine can be prepared as a virus solution containing the vaccine strain at a certain virus titer (e.g. a certain TCID.sub.50), and two or more single virus vaccines are mixed at a suitable ratio to give a combination vaccine containing each single vaccine at a predetermined amount (e.g. TCID.sub.50) or ratio.

In certain embodiments, in a combined vaccine composition comprising the PRRSV vaccine and the CSFV vaccine, the TCID.sub.50 ratio of the PRRSV vaccine to the CSFV vaccine ranges from 10000:1 to 1:1, 1000:1 to 1:1, 100:1 to 1:1, 10:1 to 1:1, or 5:1 to 1:1. For example, the vaccine composition can comprise 10.sup.4.5 TCID50 of PRRSV vaccine, and 10.sup.0.5 FA-TCID50 of CSFV vaccine, or 10.sup.4.5 TCID50 of PRRSV vaccine, and 10.sup.3.5 FA-TCID50 of CSFV vaccine, or 10.sup.5.0 TCID50 of PRRSV vaccine, and 10.sup.4.0 FA-TCID50 of CSFV vaccine.

In certain embodiments, in a combined vaccine composition comprising the PRRSV vaccine and the PRV vaccine, the TCID.sub.50 ratio of the PRRSV vaccine to the PRV vaccine ranges from 1:1 to 1:30, 1:1 to 1:25, 1:1 to 1:20, 1:1 to 1:15, 1:1 to 1:10, 1:1 to 1:9, 1:1 to 1:8, 1:1 to 1:7, 1:1 to 1:6, 1:1 to 1:5, 1:2 to 1:10, 1:3 to 1:10, 1:4 to 1:10, or 1:5 to 1:10. For example, the vaccine composition can comprise 10.sup.4.5 TCID50 of PRRSV vaccine, and 10.sup.5.5 TCID50 of PRV vaccine, or 10.sup.5.0 TCID50 of PRRSV vaccine, and 10.sup.5.5 TCID50 of PRV vaccine, or 10.sup.5.0 TCID50 of PRRSV vaccine, and 10.sup.6.5 TCID50 of PRV vaccine.

In certain embodiments, in a combined vaccine composition comprising the PRRSV vaccine, the CSFV vaccine and the PRV vaccine, the TCID.sub.50 ratio of the PRRSV vaccine:the CSFV vaccine:the PRV vaccine is about 10.sup.4:1:10.sup.5 to about 5:1:6. For example, the vaccine composition can comprise 10.sup.4.5 TCID50 of PRRSV vaccine, 10.sup.0.5 FA-TCID50 of CSFV vaccine and 10.sup.5.5 TCID50 of PRV vaccine. For another example, the vaccine composition can comprise 10.sup.4.5 TCID50 of PRRSV vaccine, 10.sup.4.0 FA-TCID50 of CSFV vaccine and 10.sup.5.5 TCID50 of PRV vaccine. For another example, the vaccine composition can comprise 10.sup.5.7 TCID50 of PRRSV vaccine, 10.sup.5.0 FA-TCID50 of CSFV vaccine and 10.sup.5.8 TCID50 of PRV vaccine. For another example, the vaccine composition can comprise 10.sup.6.0 TCID50 of PRRSV vaccine, 10.sup.5.0 FA-TCID50 of CSFV vaccine and 10.sup.6.5 TCID50 of PRV vaccine.

The vaccine compositions provided herein can further comprise an adjuvant. The adjuvant can protect the vaccine from in vivo degradation, and/or can non-specifically stimulate the immune system, thereby can be helpful to enhance the immunological response to the vaccine. Examples of adjuvants include, without limitation, mineral salts (e.g., aluminum hydroxide, aluminum phosphate, calcium hydroxide), water-in-oil emulsion (e.g., complete Freund's adjuvant, incomplete Freund's adjuvant, etc.), saponin adjuvants (e.g., Stimulon.TM., etc), derivatives of bacteria or micro-organisms (e.g., LPS, lipid A derivatives, etc) and micro-particles (e.g., poly-.alpha.-hydroxyacid, etc).

The vaccine composition provided herein can further comprise a cryoprotectant. The cryoprotectant can keep the biological products in good stability and reduce the damage to the biological activity of the vaccine during the process of lyophilization. Examples of the cryoprotectant include sucrose, L-sodium glutamate or lactalbumin hydrolysate, etc.

Methods for Preparation

In another aspect, the present disclosure provides methods for preparing the vaccine compositions provided herein, comprising: (a) collecting PRRSV vaccine strain, CSFV vaccine strain and/or PRV vaccine strain, which are cultivated in their respective susceptible cells, and (b) mixing two or more of the virus strains at a suitable TCID.sub.50 ratio.

In certain embodiments, the step (a) comprises: inoculating the PRRSV vaccine strain, CSFV vaccine strain and/or PRV vaccine strain to their respective susceptible cells, culturing the cells to prepare seed viruses for vaccine production, inoculating the seed viruses to their respective susceptible cells, propagating the cells to obtain antigen solutions containing the respective viruses.

In certain embodiments, the PRRSV vaccine strain is an attenuated vaccine strain of the highly-pathogenic PRRSV. In certain embodiments, the PRRSV vaccine strain is PRRSV TJM strain.

In certain embodiments, the CSFV vaccine strain is an attenuated CSFV. In certain embodiments, the CSFV vaccine strain is CSFV C strain (F16).

In certain embodiments, the PRV vaccine strain is an attenuated PRV. In certain embodiments, the PRV vaccine strain is Bartha K61 strain.

In certain embodiments, the susceptible cells for the PRRSV vaccine strain include, without limitation, cell lines such as Marc-145 cell line, MA-104 cell line, Vero cell line or CL-2621 cell line, or primary cells such as PAM cells.

In certain embodiments, the susceptible cells for the CSFV vaccine strain include, without limitation, cell lines such as BT cell line, Vero cell line, MPK cell line, SK6 cell line, PK2a cell line, CPK cell line, RKC cell line, MDBK cell line, MDCK cell line, CRFK cell line, PT cell line and ST cell line, or primary cells such as BT cells. Both PT cell line and ST cell line are pig testis cell lines.

In certain embodiments, the susceptible cells for the PRV vaccine strain include, without limitation, passaging cell lines such as ST cell line (ATCC No.: CRL-1746), PK-15 cell line (ATCC No.: CCL-33), Marc-145 cell line (ATCC No.: CRL-12219), bovine kidney MDBK cell line (ATCC No.: CCL-22), bovine turbinate BT cell line (ATCC No.: CRL-1390), Vero cell line (ATCC No.: CCL-81), BHK-21 cell line (ATCC No.: CCL-10), pig kidney cell line (see, IBRS-2, e.g., DECASTRO, M. P. 1964. Behavior of foot and mouth disease virus in cell culture: susceptibility of the IB-RS-2 swine cell line. Arquivos Instituto Biologica 31: 63-78), and rabbit kidney RK cell line (ATCC No.: CCL-106); or primary cells such as chicken embryo fibroblast cells and pig kidney cells. Primary cells can be prepared using methods known in the art, for example by isolating tissues from animal and preparing cells.

In certain embodiments, the susceptible cells were cultured preferably at 33-37.degree. C., in the presence of 5% CO.sub.2. The methods of culturing the susceptible cells can comprise: passaging the cell line after digestion with EDTA-trypsin solution, continuing to cultivate the cell line in growth medium, when cells reach 90-100% confluence, they can be further passaged or inoculated with a seed virus. The method for cultivating the cell line is preferably any of the following: cultivating the cells in a roller bottle and allowing the cell density to reach 1.times.10.sup.6/ml-5.times.10.sup.6/ml; or introducing an adherent carrier to a bioreactor for suspension cultivation and allowing the cell density to reach 5.times.10.sup.6/ml-1.times.10.sup.7/ml, wherein the adherent carrier is preferably a microcarrier or paper.

In certain embodiments, the PRRSV vaccine strain is inoculated to its susceptible cells at a Multiplicity of Infection (MOI) of 0.01-0.5, the CSFV vaccine strain is inoculated to its susceptible cells at a MOI of 0.1-0.5, or the inoculation amount is 3%-5% virus of cell origin, and/or the PRV vaccine strain is inoculated to its susceptible cells at a MOI of 0.005-0.5.

In certain embodiments, the cells inoculated with the respective virus vaccine strain are cultivated for 3-5 days after the inoculation, and seed viruses for vaccine production can be harvested. For PRRSV strain, the seed virus is harvested when the cytopathic effect reaches 70%. For CSFV strain, the first harvest is performed by medium change at the 5.sup.th day after the inoculation, and subsequent harvests are performed by medium change at 4-day intervals, provided that no more than five harvests are performed. For PRV strain, the cell culture medium containing the virus is harvested 2-3 days after the inoculation.

In certain embodiments, the seed virus for vaccine production has a suitable virus titer. For example, the seed virus for PRRSV TJM strain can be no less than 10.sup.7.0 TCID.sub.50 virus per ml, the seed virus for CSFV C strain (F16) can be >100,000 rabbit infective dose per ml or no less than 10.sup.6.0 FA-TCID.sub.50 virus per ml as measured by an immunofluorescence based assay, and/or the seed virus for PRV Bartha K61 strain can be no less than 10.sup.8.0 TCID.sub.50 virus per ml.

In certain embodiments, the seed viruses are inoculated to their respective susceptible cells, and are propagated to obtain antigen solutions containing the respective viruses. In certain embodiments, the antigen solutions as obtained has a suitable virus content, for example, no less than 10.sup.7.0 TCID.sub.50 virus per ml for the PRRSV TJM strain, >100,000 RID per ml or no less than 10.sup.6.0 FA-TCID.sub.50 virus per ml as measured by an immunofluorescence-based assay for the CSFV C strain (F16), and/or no less than 10.sup.8.0 TCID.sub.50 virus per ml for PRV Bartha K61 strain.

In certain embodiments, the step (b) comprises mixing the collected the PRRSV vaccine strain and the CSFV vaccine strain at a TCID.sub.50 ratio from 10000:1 to 1:1. In certain embodiments, the step (b) comprises mixing the collected PRRSV vaccine virus with the PRV vaccine virus at a TCID.sub.50 ratio from 1:1 to 1:30. In certain embodiments, the step (b) comprises mixing the collected PRRSV vaccine virus, the CSFV vaccine virus, and the PRV vaccine virus at a TCID.sub.50 ratio of about 10.sup.4:1:10.sup.5 to about 5:1:6.

In certain embodiments, the step (b) further comprises mixing the mixture of the collected virus solutions with a cryoprotectant. In certain embodiments, the mixture of the collected virus solutions is mixed with the cryoprotectant in a volume ratio of 75-80:25-20.

In another aspect, the present disclosure provides vaccine compositions prepared using the methods provided herein.

In another aspect, the present disclosure provides use of the vaccine compositions provided herein in the manufacture of a medicament for preventing or treating PRRS, CSF, and/or PR.

In another aspect, the present disclosure provides methods of immunizing a pig, comprising administering to the pig a vaccine composition provided herein.

In another aspect, the present disclosure provides CSFV vaccine strains, cultured in a cell line selected from the group consisting of ST, PK-15, Marc-145, MDBK, BT, Vero, BHK-21, porcine kidney cell line (IBRS-2), rabbit kidney cell line (RK), and chicken embryo fibroblast cell line, or a primary cell which is porcine kidney primary cells. In another aspect, the present disclosure provides use of these cell lines in culturing a CSFV vaccine strain.

The present disclosure also provides a vaccine composition prepared using the preparation method described above, comprising a PRRSV vaccine and a CSFV vaccine.

The present disclosure also provides uses of the vaccine composition in manufacturing a biological product for preventing or treating porcine reproductive and respiratory syndrome and classical swine fever.

The combination vaccine provided herein shows significant efficacy in preventing highly-pathogenic porcine reproductive and respiratory syndrome and classical swine fever. The highly-pathogenic PRRSV strains and CSFV vaccine strains provided herein do not show any immunological suppression, and the combination vaccines prepared therefrom show no difference from each of their monovalent vaccines in terms of safety, immunogenicity, duration of immunity, immunological protection, and stability. The results of safety study show that, animals which received single dose, repetitive doses, over-dose inoculation of the vaccine show normal body temperature and spirit without any clinical symptoms. The results of efficacy study show that, the vaccine provided herein can provide significant protection to animals against the challenge of virulent strains of high pathogenic PRRSV and CSFV, and can effectively prevent infection of high pathogenic PRRSV and CSFV. The results of immunity duration study show that, the duration of immunity lasts for 6 months, which can ensure effective protection to pigs during the immunity period. The results of stability study show that, the vaccine can be stored at 2-8.degree. C. for 18 months, which indicates its advantage in long shelf life and stable storage. The vaccines provided herein can be used to inoculate animals and prevent two diseases with one injection, thereby reduce the work load of vaccination and the immunization frequency, minimize the stress to the pig herds, and prevent immune tolerant and failure caused by frequent vaccination.

The present disclosure also provides a method for immunizing a pig, comprising administering the vaccine composition provided herein to the pig. The pigs can be immunized by, for example, injection. The immunization can be one single administration or repetitive administration of multiple doses. The methods for immunization or dosages can be adjusted by an experienced veterinary professional according to the actual conditions.

EXAMPLES

The following examples are intended to further illustrate the present inventions. The advantages and features of the present invention will become clear with the descriptions. However, these illustrations are merely exemplary, and should not be construed as limitations to the scope of the present disclosure.

General

Inoculation of vaccines was performed by injection into the neck muscle of the pigs. Virus challenge was performed by dripping the virus to the nose of the test pigs, and/or injecting the virus to the muscle of the test pigs. The FA-TCID.sub.50 of CSFV virus amount was measured by immunofluorescence-based method.

FACS assay for T cells. The T cells were measured by flowcytometry method. Briefly, the blood samples were treated with anti-coagulant, followed by lysis of red blood cells. The treated samples were stained with FITC-CD8 monoclonal antibody (mAb), PE-CD4 mAb, PECy5-CD3 mAb, respectively (all antibodies were purchased from 51AB Biotech, Beijing). After 45-min incubation, the unreacted antibodies were removed, and the cells were suspended with PBS and analyzed on flow cytometer (BD FACSAria).

ELISA assay. The antibodies against PRRSV antigens, antibodies against CSFV antigens were measured by ELISA, using the respective detection kits purchased from Beijing IDEXX Yuanheng Laboratories Co., Ltd.

Part I

Preparation of the Vaccines

Example 1

Preparation of PRRSV Vaccines

Cell Passage and Culture

Marc-145 cells, which were used to culture the PRRSV vaccine strain TJM, were trypsinized and divided in 1:3. The cells were cultured at 37.degree. C. in culture medium. After the cells formed a single layer, they were passaged or inoculated with a virus strain.

Propagation of the Seed Viruses in Cells

The vaccine strain TJM for highly virulent PRRSV was inoculated to Marc-145 cells in a MOI of 0.01-0.5. The inoculated cells were cultured for 3-5 days, and the virus solution was collected when the cytopathic effects (CPE) reached 70%. The collected virus solution was used as the seed virus of PRRSV TJM strain.

The seed virus was characterized according to Veterinary Pharmacopoeia of People's Republic of China. The seed virus was absent for bacteria, mold, or mycoplasma. The PRRSV seed virus solutions did not show adverse effects to pigs. The seed virus solution of PRRSV TJM strain contained no less than 10.sup.7.0 TCID.sub.50 virus per 1 ml.

Propagation of the Virus Solution for Vaccine Production

Marc-145 cells were cultured to 90-100% confluent single layer. Cell culture medium was discarded, and cells were washed twice with PBS. The seed virus solution of PRRSV TJM strain was inoculated at MOI of 0.01-0.5. The inoculated cells were cultured for 3-5 days, and the virus solution was collected when the CPE reached 70%. The collected virus solution was used as the virus solution for vaccine production. Such virus solution was characterized, and was absent for bacteria, mold, or mycoplasma, and the virus solution of PRRSV TJM strain contained no less than 10.sup.7.0 TCID.sub.50 virus per 1 ml. The virus solution was diluted appropriately to prepare PRRSV single vaccine, or mixed with other vaccines to prepare combined vaccines.

Example 2

Preparation of CSFV Vaccines

Cell Passage and Culture

The BT cells, which were used to culture the CSFV vaccine strain, were trypsinized and divided in 1:5. The cells were cultured at 37.degree. C. in culture medium. After the cells formed a single layer, they were passaged or inoculated with a virus strain.

The CSFV C strain (F16) was prepared into a 0.3% virus solution, and was inoculated to a single layer of BT cells. The inoculated cells were cultured for 5 days, and the virus solution is collected as the seed virus of CSFV vaccine strain.

Characterization of the Seed Viruses

The seed viruses were characterized according to Veterinary Pharmacopoeia of People's Republic of China. The seed viruses were absent for bacteria, mold, or mycoplasma. The CSFV C strain (F16) were tested as a qualified seed virus solution, and showed no adverse effects to pigs. The seed virus solution of CSFV C strain (F16) contained >100,000 rabbit infective dose (RID), or no less than 10.sup.6.0 FA-TCID.sub.50 virus per 1 ml virus solution as measured by an immunofluorescence-based method.

Propagation of the Virus Solution for Vaccine Production

BT cells were cultured to 90-100% confluent single layer. Cell culture medium was discarded, and cells were washed twice with PBS. The seed virus solution of CSFV C strain (F16) was inoculated at MOI of 0.1-0.5 or at an amount of 3%-5%. At the 5.sup.th day after the inoculation, the first harvest is performed by medium change, and the subsequent harvests are performed at 4-day intervals, provided that no more than 5 harvests are performed. The virus solutions as collected were stored under -20.degree. C. and used as the virus solution for vaccine production. Such virus solution was characterized, and the seed virus solution of CSFV C strain (F16) contained >100,000 RID, or no less than 10.sup.6.0 FA-TCID.sub.50 virus per 1 ml virus solution as measured by an immunofluorescence-based method. The virus solution was diluted appropriately to prepare CSFV single vaccine, or mixed with other vaccines to prepare combined vaccines.

Example 3

Preparation of PRV Vaccines

Cell Passage and Culture

Marc-145 cells, MDBK cells and BT cells which were used to culture the PRV vaccine strain Bartha K61, were trypsinized and passaged respectively in cell growth medium. The cells were cultured at 37.degree. C. in culture medium. After the cells formed a single layer, they were passaged or inoculated respectively with a virus strain.

Propagation of the Seed Virus in Cells

The PRV vaccine strain Bartha K61 was inoculated to a single layer of Marc-145 cells, MDBK cells or BT cells in MEM medium containing 2-4% bovine serum. The inoculated cells were cultured respectively for 2-3 days, and the virus solutions were collected as the seed virus of PRV vaccine strain.

Characterization of the Seed Viruses

The seed viruses were characterized. The PRV seed viruses were tested as a qualified seed solution, and did not show adverse effects to pigs. The seed virus solution of PRV strain contained no less than 10.sup.8.0 TCID.sub.50 virus per 1 ml.

Propagation of the Virus Solution of the PRV Vaccine Strain

The PRV stain was inoculated to a confluent single layer of Marc-145 cells, MDBK cells or BT cells at MOI of 0.005-0.5 with maintenance medium added. The inoculated cells were cultured at 36-37.degree. C. and the virus solution was collected when CPE reached 70%.

The amount of the virus solution was measured after freeze-thaw for 2 cycles. The seed virus solution contained no less than 10.sup.8.0 TCID.sub.50 virus per 1 ml. The virus solution was characterized in accordance with the Veterinary Pharmacopoeia of People's Republic of China, and was absent for bacteria, mold, or mycoplasma. The qualified virus solutions were stored under -15.degree. C. and used as the virus solution for vaccine production. The virus solution was diluted appropriately to prepare PRV single vaccine, or mixed with other vaccines to prepare combined vaccines.

Example 4

Preparation of a Combined Vaccine Composition for PRRSV and CSFV

Antigen solution was prepared by combining the virus solution of PRRSV TJM strain (prepared according to Example 1) and the virus solution of CSFV C strain (F16) (prepared according to Example 2).

Heat-resistant cryoprotectant was prepared by mixing sucrose, L-sodium glutamate, and lactalbumin hydrolysate in a suitable ratio, followed by autoclave.

75-80 of volume fraction of the antigen solution was mixed with 25-20 of volume fraction of the cryoprotectant, and the mixture was filed into ampoules in a predetermined amount. The ampoules were capped and were subject to low temperature and drying process to get freeze-dried vaccine composition. The vaccine composition was tested for sterility, safety, and efficacy.

In each dose of the combined PRRSV and CSFV vaccine as prepared, the amount of PRRSV TJM strain was .gtoreq.10.sup.5.0 TCID.sub.50, and the amount of CSFV C strain (F16) was .gtoreq.7500 RID (or .gtoreq.750 RID, or .gtoreq.150 RID), or no less than 10.sup.4.0 FA-TCID.sub.50 virus as measured by an immunofluorescence-based method.

The combined vaccine was characterized according to page 15, 19 and 20 of the appendix of Veterinary Pharmacopoeia of People's Republic of China. The combined vaccine was absent for bacteria, mold, mycoplasma and exogenous virus.

Example 5

Preparation of a Combined Vaccine Composition for PRRSV and PRV

Antigen solution was prepared by combining the virus solution of PRRSV TJM strain (prepared according to Example 1) and the virus solution of PRV Bartha K61 strain (prepared according to Example 3).

Heat-resistant cryoprotectant was prepared by mixing sucrose, L-sodium glutamate, and lactalbumin hydrolysate in a suitable ratio, followed by autoclave.

6-8 of volume fraction of the antigen solution was mixed with 2-4 of volume fraction of the cryoprotectant, and the mixture was filed into ampoules in a predetermined amount. The ampoules were capped and were subject to low temperature and drying process to get freeze-dried vaccine composition.

In each dose of the combined PRRSV and PRV vaccine as prepared, the amount of PRRSV TJM strain was .gtoreq.10.sup.5.0 TCID.sub.50, and the amount of PRV Bartha K61 strain was .gtoreq.10.sup.5.5 TCID.sub.50.

The combined vaccine was characterized according to page 15, 19 and 20 of the appendix of Veterinary Pharmacopoeia of People's Republic of China. The combined vaccine was absent for bacteria, mold, mycoplasma and exogenous virus.

Example 6

Preparation of a Combined Vaccine Composition for PRRSV, CSFV and PRV

Antigen solution was prepared by combining the virus solution of PRRSV TJM strain (prepared according to Example 1), the virus solution of CSFV C strain (F16) (prepared according to Example 2), and the virus solution of PRV Bartha K61 strain (prepared according to Example 3).

Heat-resistant cryoprotectant was prepared by mixing sucrose, L-sodium glutamate, and lactalbumin hydrolysate in a suitable ratio, followed by autoclave.

75-80 of volume fraction of the antigen solution was mixed with 25-20 of volume fraction of the cryoprotectant, and the mixture was filed into ampoules in a predetermined amount. The ampoules were freeze-dried to provide the vaccine composition. The vaccine composition was tested for sterility, safety, and efficacy.

In each dose of the combined PRRSV, CSFV and PRV vaccine as prepared, the amount of PRRSV TJM strain virus was .gtoreq.10.sup.5.0 TCID.sub.50, the amount of CSFV C strain virus was .gtoreq.7500 RID (or .gtoreq.750 RID, .gtoreq.150 RID), or no less than 10.sup.4.0 FA-TCID.sub.50 virus as measured by an immunofluorescence-based method and the amount of PRV Bartha K61 strain virus was .gtoreq.10.sup.5.5 TCID.sub.50.

The combined vaccine was characterized according to page 15, 19 and 20 of the appendix of Veterinary Pharmacopoeia of People's Republic of China. The combined vaccine was absent for bacteria, mold, mycoplasma and exogenous virus.

Example 7

Gene Characterization of PRRSV TJM Strain

The PRRSV TJM strain contained in the virus solution as prepared according to Example 1, and in the combination vaccines as prepared according to Examples 4-6 was characterized by PCR, using primers specific to nsp2 of PRRSV (forward primer: 5'-GGCAAGAAGTTGAGGAAGT-3'; reverse primer: 5'-TGGCAGGTTGGTCACAGA-3'). PRRSV TJ strain was a positive control and water was a negative control.

The results showed a specific 207 bp band in the samples containing PRRSV TJM strain, as compared to a 567 bp band in the positive control containing PRRSV TJ strain (FIG. 5). The results confirmed that PRRSV TJM strain lacks 360 nucleotides in nsp2 gene, and further confirmed that the vaccines as prepared is not contaminated with PRRSV TJ strain.

Example 8

Gene Characterization of PRV Bartha K61 Strain

The PRV Bartha K61 strain contained in the virus solution as prepared according to Example 3, and in combination vaccine compositions as prepared according to Examples 5-6 was characterized by PCR, using primers specific to gE of PRV (forward primer: 5'-CGTCACGGTCACCAAGGAGC-3'; reverse primer: 5'-GCACAGCACGCAGAGCCAG-3'). PRV virulent strain (JL1 strain) was a positive control and water was a negative control.

According to the results, no band was found in the samples containing PRV Bartha K61 strain, as compared to a 232 bp band in PRV virulent strain (FIG. 6).

The results confirmed that PRV Bartha K61 strain contains deletion in gE gene, and further confirmed that the vaccines as prepared is not contaminated with PRV virulent strain.

Part II

Efficacy Studies

Example 9

Determination of Minimum Immunologically Effective Dose for PRRSV TJM Strain

25 healthy weaning pigs were used in the study. The pigs were negative for highly-pathogenic PRRSV, in terms of both antigen and antibody. The pigs were randomized in 5 groups. Group I to VI were inoculated with different doses of PRRSV TJM strain, while Group V was kept as negative control (Table 1). Pigs were challenged with virulent PRRSV TJ strain, and protection rates were calculated after the study. According to Table 1, PRRSV TJM strain at 10.sup.4.5 TCID50 or higher amount was sufficient to induce protective immunity in pigs, with a protection rate of 4/5.

TABLE-US-00001 TABLE 1 No. of No. of No. sick/ dead/ of Vaccination Virus challenge dosage/ No. of No. of Protection Group pigs dosage/pig pig tested tested rates I 5 10.sup.5.5 TCID.sub.50 2 .times. 10.sup.4.0-2 .times. 10.sup.4.5 TCID.sub.50 1/5 0/5 4/5 II 5 10.sup.4.5 TCID.sub.50 2 .times. 10.sup.4.0-2 .times. 10.sup.4.5 TCID.sub.50 1/5 0/5 4/5 III 5 10.sup.3.5 TCID.sub.50 2 .times. 10.sup.4.0-2 .times. 10.sup.4.5 TCID.sub.50 3/5 0/5 2/5 IV 5 10.sup.2.5 TCID.sub.50 2 .times. 10.sup.4.0-2 .times. 10.sup.4.5 TCID.sub.50 5/5 1/5 0/5 V 5 PBS 2 .times. 10.sup.4.0-2 .times. 10.sup.4.5 TCID.sub.50 5/5 2/5 0/5

Example 10

Determination of Minimum Immunologically Effective Dose for CSFV C Strain (F16)

28 healthy weaning pigs were used in the study. The pigs were negative for CSFV, in terms of both antigen and antibody. The pigs were randomized in 6 groups. Group I to V were inoculated with different doses of CSFV C strain (F16), while Group VI was kept as negative control (Table 2). Pigs were challenged with virulent CSFV Shimen strain, and protection rates were calculated after the study. According to Table 2, CSFV C strain (F16) at 10.sup.0.5 TCID50 or higher amount was sufficient to induce protective immunity in pigs, with a protection rate of 5/5.

TABLE-US-00002 TABLE 2 No. Virus No. of No. of of Vaccination challenge sick/No. dead/No. Group pigs dosage/pig dosage/pig of tested of tested Protection rates I 5 10.sup.4.5 FA TCID.sub.50 10.sup.6.0 MLD 0/5 0/5 5/5 II 5 10.sup.3.5 FA TCID.sub.50 10.sup.6.0 MLD 0/5 0/5 5/5 III 5 10.sup.2.5 FA TCID.sub.50 10.sup.6.0 MLD 0/5 0/5 5/5 IV 5 10.sup.1.5 FA TCID.sub.50 10.sup.6.0 MLD 0/5 0/5 5/5 V 5 10.sup.0.5 FA TCID.sub.50 10.sup.6.0 MLD 0/5 0/5 5/5 VI 3 PBS 10.sup.6.0 MLD 3/3 3/3 0/3 MLD: Minimum lethal dose.

Example 11

Determination of Minimum Immunologically Effective Dose for Combined Vaccine of PRRSV TJM Strain and CSFV C Strain (F16)

40 healthy piglets were used in the study. The pigs were negative for both highly-pathogenic PRRSV and CSFV, in terms of both antigen and antibody. The pigs were randomized in 4 groups. Groups I to III groups were inoculated with different doses of the combined vaccines of PRRSV TJM strain and CSFV C strain (F16), while Group IV was kept as a negative control. Half of the pigs in each group were challenged with PRRSV TJ strain, and the other half were challenged with CSFV Shimen strain. Protection rates were calculated after the study.

According to Table 3, combined vaccine containing 10.sup.4.5 TCID50 of PRRSV TJM and 10.sup.3.5 FA-TCID50 of CSFV C strain (F16) was sufficient to induce protective immunity in pigs (Tables 3 and 4). In particular, CSFV C strain (F16) demonstrated 100% protection in all dosages as tested in the combined vaccine, indicating that the immune response to CSFV C strain (F16) was not suppressed by PRRSV TJM strain. Moreover, in view of the extremely low immunologically effective dosage of CSFV C strain (F16) as demonstrated in Example 10, lower dosages of CSFV C strain (F16) can be used in the combined vaccine without reducing the protection rate.

TABLE-US-00003 TABLE 3 No. PRRSV TJ No. of sick/ No. of dead/ of challenge No. of No. of Protection Group pigs Vaccination dosage/pig dosage/pig tested tested rates I 5 PRRSV TJM: 10.sup.5.5 TCID.sub.50; 2 .times. 10.sup.4.0-2 .times. 10.sup.4.5 0/5 0/5 5/5 CSFV C strain (F16): 10.sup.4.5 TCID.sub.50 FA-TCID.sub.50 II 5 PRRSV TJM: 10.sup.4.5 TCID.sub.50; 2 .times. 10.sup.4.0-2 .times. 10.sup.4.5 0/5 0/5 5/5 CSFV C strain (F16): 10.sup.3.5 TCID.sub.50 FA-TCID.sub.50 III 5 PRRSV TJM: 10.sup.3.5 TCID.sub.50; 2 .times. 10.sup.4.0-2 .times. 10.sup.4.5 2/5 0/5 3/5 CSFV C strain (F16): 10.sup.2.5 TCID.sub.50 FA-TCID.sub.50 IV 5 PBS 2 .times. 10.sup.4.0-2 .times. 10.sup.4.5 5/5 4/5 0/5 TCID.sub.50

TABLE-US-00004 TABLE 4 No. CSFV Shimen No. of sick/ No. of dead/ of challenge No. of No. of Protection Group pigs Vaccination dosage/pig dosage/pig tested tested rates I 5 PRRSV TJM: 10.sup.5.5 TCID.sub.50; 10.sup.6.0 MLD 0/5 0/5 5/5 CSFV C strain (F16): 10.sup.4.5 FA-TCID.sub.50 II 5 PRRSV TJM: 10.sup.4.5 TCID.sub.50; 10.sup.6.0 MLD 0/5 0/5 5/5 CSFV C strain (F16): 10.sup.3.5 FA-TCID.sub.50 III 5 PRRSV TJM: 10.sup.3.5 TCID.sub.50; 10.sup.6.0 MLD 0/5 0/5 5/5 CSFV C strain (F16): 10.sup.2.5 FA-TCID.sub.50 IV 5 PBS 10.sup.6.0 MLD 5/5 5/5 0/5

Example 12

Combined PRRSV TJM Strain and CSFV C Strain (F16) does not have Immuno-Inhibition

30 healthy pigs aged 21-28 days were used in the study. The pigs were negative for both highly-pathogenic PRRSV and CSFV, in terms of both antigen and antibody. The pigs were randomized in 7 groups, with 5 pigs in each of Groups I to V, 3 pigs in Group VI and 2 pigs in Group VII (Table 5). Each pig was inoculated with 1 ml of the testing sample, or not inoculated at all (i.e. Group VII), according to the study design shown in Table 5.

TABLE-US-00005 TABLE 5 No. of Group pigs Testing sample Amount Vaccine dose I 5 PRRSV TJM 1 ml 10.sup.5.0 TCID.sub.50/ml II 5 CSFV C strain 1 ml 7500 RID/ml (F16) (or 10.sup.4.0 FA-TCID.sub.50/ml) III 5 PRRSV TJM + 1 ml PRRSV: 10.sup.5.0 TCID.sub.50/ml CSFV C strain CSFV: 7500RID (F16) (or 10.sup.4.0 FA-TCID.sub.50/ml) IV 5 PRRSV TJM + 1 ml PRRSV: 10.sup.5.0 TCID.sub.50/ml CSFV C strain CSFV: 7500RID (F16) (or 10.sup.4.0 FA-TCID.sub.50/ml) V 5 PBS 1 ml N/A VI 3 PBS 1 ml N/A VII 2 N/A N/A N/A "RID": rabbit infective dose; "N/A": No inoculation or vaccination was performed.

Rectal temperatures of the pigs were taken each day from the 3.sup.rd day before the vaccination until the 14.sup.th day after the vaccination. Body weights were measured every 7 days. The pigs were also under close clinical observation. Blood samples were taken from each of the pigs in the study at the 3.sup.rd day before the vaccination, the 0 day, 3.sup.rd day, 7.sup.th day, 10.sup.th day, 14.sup.th day, 21.sup.st day, and 28.sup.th day after the vaccination, respectively. Each blood sample was divided into two portions. One was treated with an anticoagulant, and was used for detection of CD3.sup.+, CD4.sup.+, CD8.sup.+ and CD4.sup.+ CD8.sup.+ T cells. The other portion was treated with a coagulant, and was used for antibody titer assay.

Results showed that the changes in CD3.sup.+, CD4.sup.+, CD8.sup.+ and CD4.sup.+CD8.sup.+ T cells in the vaccinated pigs were similar to those observed in the pigs of the control groups (FIGS. 7-10). After vaccination with the combined vaccines, pigs in Groups III and IV produced antibodies against both viruses, and such antibody productions did not interfere with each other (FIGS. 11-12). The kinetics of PRRSV antibody production for pigs in Groups III and IV was similar to those for pigs in Group I, and the kinetics for CSFV antibody production for pigs in Groups III and IV was similar to those for pigs in Group II. The results showed that, vaccination of PRRSV TJM strain does not inhibit the immunological response against CSFV C strain (F16), and vice versa.

The rectal temperatures and the body weights of the pigs in each group do not show significant difference (FIG. 13).

At the 28.sup.th day after the vaccination, the pigs were challenged with virulent viruses, according to the study design shown in Table 6. After the virus challenge, rectal temperatures of the pigs were taken each day, and the pigs were observed for clinical manifestations including appetite, breathing, and spirits. Blood samples were taken from each of the pigs at the 0 day, 3.sup.rd day, 7.sup.th day, 10.sup.th day, and 14.sup.th day respectively, after the virus challenge, and were treated with an anticoagulant for detection of CD3.sup.+, CD4.sup.+, CD8.sup.+ and CD4.sup.+CD8.sup.+ T cells. Blood samples were also taken on the day of virus challenge and each other day after the challenge, for isolation of PRRSV virus and CSFV virus, and determination of presence of viremia. Clinical protection rates, morbidity (i.e. number of sick pigs/number of tested pigs), and mortality (i.e. number of dead pigs/number of tested pigs) were calculated for each group of animals 14 days after the virus challenge study, and the results are shown in Table 6.

TABLE-US-00006 TABLE 6 No. of dead/ Pig Challenge Challenge No. of sick/ No. of Protection Group No. sample dose/pig No. of tested tested Rate I 5 PRRSV TJ 2 .times. 10.sup.4.0-2 .times. 10.sup.4.5 0/5 0/5 5/5 TCID.sub.50 II 5 CSFV 10.sup.6.0 MLD 0/5 0/5 5/5 Shimen III 5 PRRSV TJ 2 .times. 10.sup.4.0-2 .times. 10.sup.4.5 0/5 0/5 5/5 TCID.sub.50 IV 5 CSFV 10.sup.6.0 MLD 0/5 0/5 5/5 Shimen V 5 PRRSV TJ 2 .times. 10.sup.4.0-2 .times. 10.sup.4.5 5/5 3/5 0/5 TCID.sub.50 VI 3 CSFV 10.sup.6.0 MLD 3/3 3/3 0/3 Shimen VII 2 N/A N/A N/A N/A N/A "MLD": minimum lethal dose; "N/A": No inoculation or vaccination was performed.

Results showed that, after the virus challenge, body temperatures were elevated in non-vaccinated pigs of Groups V and VI, but not in vaccinated pigs of Groups I-IV (FIGS. 14-15). Pigs in Group V demonstrated clinical symptoms for highly-pathogenic PRRS such as low spirit, stress in breath, red skin, etc. Pigs in Group VI demonstrated significant symptoms for classical swine fever, including low spirit, constipation followed by diarrhea, red skin, etc. No pigs in the vaccinated groups demonstrated such clinical symptoms (FIGS. 16-17).

After the virus challenge, non-vaccinated pigs of Groups V and VI showed a significant drop in CD3.sup.+, CD4.sup.+, CD8.sup.+ and CD4.sup.+CD8.sup.+ T cells, and started to die from 7.sup.th day after the virus challenge. On the other hand, pigs vaccinated with the combined vaccines or the single vaccines did not show such significant drop in T cells, and the T cell profiles were comparable to the healthy pigs in the blank control group. This indicated that the vaccines were effective in eliciting cellular immune responses. In addition, the pigs vaccinated with the combined vaccines and the pig with the single vaccines showed similar changes in CD3.sup.+, CD4.sup.+, CD8.sup.+ and CD4.sup.+CD8.sup.+ T cells, which indicated that the combined vaccines were free from immuno-inhibition against each other (FIGS. 18-25).

After challenge with highly virulent PRRSV, non-vaccinated pigs of Group V started to develop viremia from day 2, which lasted up to 11 days. However, pigs vaccinated with the combined vaccines or the PRRSV single vaccine did not develop viremia until day 4, which lasted up to 5 days. This indicated that the combined vaccines and the single vaccine both provided effective protection against infection of highly-pathogenic PRRSV, and the combined vaccines were free from immuno-inhibition against each other.

After challenge with virulent CSFV, all pigs in Group VI developed viremia, but none of the vaccinated pigs developed viremia. This indicated that the combined vaccines and the single vaccine both provided effective protection against infection of virulent CSFV, and the combined vaccines were free from immuno-inhibition against each other.

Example 13

Efficacy Study of the 2-Combo Vaccine for PRRSV and CSFV

Efficacy study was carried out using three batches of the lab-made 2-combo vaccine for PRRSV and CSFV (Batch No.: 200904, 200905, and 200906), prepared according to Example 4.

28 healthy pigs, negative for both highly virulent PRRSV and CSFV, in terms of both antigen and antibody, were used in the study for each batch of the 2-combo vaccine sample. The pigs were randomized in 6 groups, with 5 pigs in each of Groups I to IV and Group VI, and 3 pigs in Group V. Each group of pigs was inoculated with its respective testing sample, and at the 28.sup.th day after the vaccination, the pigs were challenged with a virulent virus, in accordance with the study design shown in Table 7.

TABLE-US-00007 TABLE 7 Virus challenge and Protective rates Group Testing sample and dosage dosage/pig 200904 200905 200906 I 2-combo vaccine, 1 ml/pig: CSFV Shimen: 5/5 5/5 5/5 PRRSV TJM (10.sup.5.0 TCID.sub.50/ml) + 10.sup.6.0 MLD CSFV C strain (F16) (7500 RID/ml, or 10.sup.4.0 FA-TCID.sub.50/ml) II 2-combo vaccine, 1 ml/pig: PRRSV TJ, 4/5 4/5 5/5 PRRSV TJM (10.sup.5.0 TCID.sub.50/ml) + 2 .times. 10.sup.4.0-2 .times. 10.sup.4.5 CSFV C strain (F16) (7500RID/ml, TCID.sub.50 or 10.sup.4.0 FA-TCID.sub.50/ml) III CSFV C strain (F16), 1 ml/pig: CSFV Shimen: 5/5 5/5 5/5 7500 RID/ml, or 10.sup.4.0 10.sup.6.0 MLD FA-TCID.sub.50/ml IV PRRSV TJM, 1 ml/pig: PRRSV TJ, 5/5 4/5 4/5 10.sup.5.0 TCID.sub.50/ml 2 .times. 10.sup.4.0-2 .times. 10.sup.4.5 TCID.sub.50 V PBS, 1 ml/pig CSFV Shimen: 0/3 0/3 0/3 10.sup.6.0 MLD VI PBS, 1 ml/pig PRRSV TJ, 0/5 0/5 0/5 2 .times. 10.sup.4.0-2 .times. 10.sup.4.5 TCID.sub.5.0 "RID": rabbit infective dose; "MLD": minimum lethal dose;

The CSFV virus challenge study ended at the 16.sup.th day after the challenge, and the PRRSV virus challenge study ended at the 21.sup.st day after the challenge. The protection rates were calculated and the results are shown in Table 7. All of the three batches of the 2-combo vaccines of PRRSV and CSFV demonstrated good protection against the challenge from highly virulent PRRSV or CSFV. The protection from the 2-combo vaccine showed no significant difference from the single vaccine controls. The un-vaccinated pigs all showed evident clinical symptoms of infection.

Example 14

Immuno-Duration Study of the 2-Combo Vaccine for PRRSV and CSFV

Immuno-duration study was carried out using the 2-combo vaccine for PRRSV and CSFV (as prepared according to Example 4). PRRSV single vaccine (as prepared according to Example 1) and CSFV single vaccine (as prepared according to Example 2) were used as controls.

56 healthy pigs were used in the immuno-duration study. All pigs were negative for PRRSV and CSFV, in terms of both antigen and antibody. The pigs were randomized into 6 groups, and were inoculated with the respective testing samples as shown in Table 8. Blood samples were collected for determination of antibody titers at 1st, 2nd, 3rd, 4th, 5th, or 6th months post vaccination.

At the 3rd and the 6th month post vaccination, respectively, half of the animals were taken from each study group. These animals were challenged with the respective virulent virus, as shown in Table 8.

Results showed that (see Table 8), the 2-combo vaccines provided effective protection to pigs against virus challenge 6 months after the vaccination, and therefore supported a 6-month immuno-duration period. The immuno-duration of the 2-combo vaccine was found comparable to that of the single vaccines.

TABLE-US-00008 TABLE 8 Virus challenge and dosage/ Protective rates Group Vaccine inoculation and dosage pig 3-mon 6-mon I 2-combo vaccine, 1 ml/pig: CSFV Shimen strain 5/5 5/5 PRRSV TJM (10.sup.5.0 TCID.sub.50/ml) + 10.sup.6.0 MLD CSFV C strain (F16) (7500 RID, or 10.sup.4.0 FA-TCID.sub.50/ml) II 2-combo vaccine, 1 ml/pig: PRRSV TJ strain, 5/5 5/5 PRRSV TJM (10.sup.5.0 TCID.sub.50/ml) + 2 .times. 10.sup.4.0-2 .times. 10.sup.4.5 TCID.sub.50 CSFV C strain (F16) (7500 RID, or 10.sup.4.0 FA-TCID.sub.50/ml) III CSFV C strain (F16), 1 ml/pig: CSFV Shimen strain 5/5 5/5 7500 RID, or 10.sup.4.0 FA-TCID.sub.50/ml 10.sup.6.0 MLD IV PRRSV TJM, 1 ml/pig: PRRSV TJ strain, 4/5 4/5 10.sup.5.0 TCID.sub.50/ml 2 .times. 10.sup.4.0-2 .times. 10.sup.4.5 TCID.sub.50 V PBS, 1 ml/pig: CSFV Shimen strain 0/3 0/3 10.sup.6.0 MLD VI PBS, 1 ml/pig: PRRSV TJ strain, 0/5 0/5 2 .times. 10.sup.4.0-2 .times. 10.sup.4.5 TCID.sub.50 "RID": rabbit infective dose; "MLD": minimum lethal dose;

Example 15

Combined PRRSV TJM Strain and PRV Bartha K61 Strain does not have Immuno-Inhibition

2-combo vaccine for PRRSV TJM and PRV Bartha K61 (prepared according to Example 5) was used in the study. Pigs aged 4-5 weeks were randomized in 4 groups, with 4 pigs in each group. All pigs were negative for PRRSV and PRV, in terms of both antigen and antibody.

Pigs were inoculated with the respective testing sample, according to the study design shown in Table 9. The second vaccination was performed one week after the first vaccination.

TABLE-US-00009 TABLE 9 Group First vaccination Second vaccination I PRRSV TJM, 1 ml/pig: PRV Bartha K61, 1 ml: 10.sup.5.0 TCID.sub.50/ml 10.sup.5.5 TCID.sub.50/ml II N/A 2-combo vaccine, 1 ml: PRRSV TJM (10.sup.5.0 TCID.sub.50/ml) + PRV Bartha K61(10.sup.5.5 TCID.sub.50/ml) III N/A PRV Bartha K61, 1 ml (10.sup.5.5 TCID.sub.50/ml) IV N/A PBS "N/A": No inoculation or vaccination was performed.

After the vaccination, blood samples of the pigs were collected each week, until the 28.sup.th day after the vaccination. The blood samples were treated and detected for antibody titers against PRV.

Results showed that (FIG. 26), the PRV antibody titer was not significantly different among Groups I to III. This suggested that PRRSV TJM strain did not have immuno-inhibition against the PRV vaccine. PRRSV TJM strain did not affect the PRV antibody titer when administered separately or as a combined vaccine with PRV. The 2-combo vaccine for PRRSV and PRV had an efficacy comparable to that of a PRV single vaccine.

Example 16

Efficacy Study of the Combined PRRSV and PRV Vaccine

Efficacy study was carried out using three batches of the 2-combo vaccines for PRRSV and PRV, prepared according to Example 5.

Pigs aged 4-5 weeks were randomized into 4 groups, with 10 pigs in each group. Groups I to III were injected with one dose of a respective batch of 2-combo vaccine. Each dose of the vaccine contained 10.sup.50 TCID.sub.50/ml PRRSV TJM strain and 10.sup.5.5 TCID.sub.50/ml PRV Bartha K61 strain. Group IV was a control group and was injected with 1 ml MEM medium.

After the vaccination, the pigs were observed for clinical manifestations and adverse effects. The blood of the pigs was collected each week, and serum was separated for characterization of the antibody titers. The body weight of the pigs was measured every week.

4 weeks after the vaccination, 5 pigs in each group were challenged with PRRSV TJ strain at a dose of 2.times.10.sup.4.0-2.times.10.sup.4.5 TCID.sub.50, and the other 5 pigs were challenged with PRV virulent strain (JL1 strain) at a dose of 10.sup.3.0-10.sup.3.5 TCID.sub.50. After the virus challenge, the pigs were observed for clinical manifestations including appetite and spirit. Rectal temperatures of the pigs were taken each day. Blood samples and nasal swabs were collected for virus characterization.

Results showed that, vaccinated pigs in Groups I to III showed normal temperature and were in good spirits and good appetites after vaccination. After the virus challenge, the vaccinated pigs were protected with a protective rate of above 4/5, while all of the non-vaccinated pigs in the control group developed infection, and had a mortality rate of 2/5 from virulent PRRSV challenge and 3/5 from virulent PRV challenge. The results suggested that the 2-combo vaccine for PRRSV and PRV had good efficacy against the challenge of both viruses, and were effective in preventing infection of PRRSV and PRV.

Example 17

Combined PRRSV TJM Strain, CSFV C Strain and PRV Bartha K61 Strain does not have Immuno-Inhibition

46 healthy pigs aged 21-28 days were used in the study. The pigs were negative for highly virulent PRRSV, CSFV and PRV, in terms of both antigen and antibody. The pigs were randomized into 10 groups, with 5 pigs in each of Groups I to VII and Group IX, and 3 pigs in each of Groups VIII and X. The pigs were inoculated with 1 ml of the testing sample as assigned, or not inoculated at all (i.e. Group X), according to the study design shown in Table 10.

TABLE-US-00010 TABLE 10 No. of Group pigs Testing sample Vaccine dose I 5 PRRSV TJM, 1 ml/pig 10.sup.5.0 TCID.sub.50/ml II 5 CSFV C strain (F16), 7500 RID/ml 1 ml/pig (or 10.sup.4.0 FA-TCID.sub.50/ml) III 5 PRV Bartha K61, 1 ml/pig 10.sup.5.5 TCID.sub.50/ml IV 5 3-combo vaccine, 1 ml/pig: PRRSV: 10.sup.5.0 TCID.sub.50/ml PRRSV TJM + CSFV: 7500 RID/ml CSFV C strain (F16) + (or 10.sup.4.0 FA-TCID.sub.50/ml) PRV Bartha K61 PRV: 10.sup.5.5 TCID.sub.50/ml V 5 3-combo vaccine, 1 ml/pig: PRRSV: 10.sup.5.0 TCID.sub.50/ml PRRSV TJM + CSFV: 7500 RID/ml CSFV C strain (F16) + (or 10.sup.4.0 FA-TCID.sub.50/ml) PRV Bartha K61 PRV: 10.sup.5.5 TCID.sub.50/ml VI 5 3-combo vaccine, 1 ml/pig: PRRSV: 10.sup.5.0 TCID.sub.50/ml PRRSV TJM + CSFV: 7500 RID/ml CSFV C strain (F16) + (or 10.sup.4.0 FA-TCID.sub.50/ml) PRV Bartha K61 PRV: 10.sup.5.5 TCID.sub.50/ml VII 5 PBS, 1 ml/pig N/A VIII 3 PBS, 1 ml/pig N/A IX 5 PBS, 1 ml/pig N/A X 3 N/A N/A "RID": rabbit infective dose. "N/A": No inoculation or vaccination was performed.

Rectal temperatures of the pigs were taken each day from the 3.sup.rd day before the vaccination until the 7.sup.th day after the vaccination. The pigs were also under close clinical observation. Blood samples were taken from each of the pigs in the study at the 3.sup.rd day before the vaccination, the 0 day, 3.sup.rd day, 7.sup.th day, 10.sup.th day, 14.sup.th day, 21.sup.st day, 28.sup.th day, 31.sup.st day, 35.sup.th day, 38.sup.th day, and 42.sup.nd day after the vaccination, respectively. Each blood sample was divided into two portions. One was treated with an anticoagulant, and was used for detection of CD3.sup.+, CD4.sup.+, and CD8.sup.+ T cell detection. The other portion was treated with a coagulant, and was used for antibody titer assay.

At the 28.sup.th day after the vaccination, the pigs were challenged with virulent viruses, according to the study design shown in Table 11. After the virus challenge, rectal temperatures of the pigs were taken each day, and the pigs were observed for clinical manifestations including appetite, breathing, and spirits. The PRRSV challenge study ended at 21.sup.st day after the virus challenge, and the CSFV challenge study ended at the 16.sup.th day after the virus challenge. Clinical protection rates, morbidity (i.e. number of sick pigs/number of tested pigs), and mortality (i.e. number of dead pigs/number of tested pigs) were calculated for each group after the virus challenge study, and the results are shown in Table 11.

TABLE-US-00011 TABLE 11 No. of No. of Pig Challenge sick/No. dead/ No. Protection Group No. sample Challenge dose/pig of tested of tested Rate I 5 PRRSV TJ 2 .times. 10.sup.4.0-2 .times. 10.sup.4.5 TCID.sub.50 0/5 0/5 5/5 II 5 CSFV Shimen 10.sup.6.0 MLD 0/5 0/5 5/5 III 5 PRV JL1 10.sup.3.0-10.sup.3.5 TCID.sub.50 0/5 0/5 5/5 IV 5 PRRSV TJ 2 .times. 10.sup.4.0-2 .times. 10.sup.4.5 TCID.sub.50 0/5 0/5 5/5 V 5 CSFV Shimen 10.sup.6.0 MLD 0/5 0/5 5/5 VI 5 PRV JL1 10.sup.3.0-10.sup.3.5 TCID.sub.50 0/5 0/5 5/5 VII 5 PRRSV TJ 2 .times. 10.sup.4.0-2 .times. 10.sup.4.5 TCID.sub.50 5/5 3/5 0/5 VIII 3 CSFV Shimen 10.sup.6.0 MLD 3/3 3/3 0/3 IX 5 PRV JL1 10.sup.3.0-10.sup.3.5 TCID.sub.50 5/5 5/5 0/5 X 3 N/A N/A N/A N/A N/A "MLD": minimum lethal dose; "N/A": No inoculation or vaccination was performed.

Results showed that PRRSV TJM strain, when combined with the CSFV C strain and the PRV Bartha K61 strain, provided effective protection against challenge of all three virulent viruses. The combined vaccines showed comparable efficacy to that of each single vaccines, suggesting that the combined vaccines were free from immuno-inhibition against each other.

Example 18

Efficacy Study for Combined PRRSV TJM Strain, CSFV C Strain and PRV Bartha K61 Strain

Efficacy study was carried out using three batches of the lab-made 3-combo vaccine (batch No.: 031-01, 031-02, and 031-03), prepared according to Example 6.

43 healthy pigs, negative for highly virulent PRRSV, CSFV and PRV, in terms of both antigen and antibody, were used in the study. The pigs were randomized in 9 groups, with 5 pigs in each of Groups I to VI, Group VIII and Group IX, and 3 pigs in Group VII. Each group of pigs was inoculated with its respective testing sample, and at the 28.sup.th day after the vaccination, the pigs were challenged with a respective virulent virus, in accordance with the study design shown in Table 12. The PRRSV challenge study ended at 21.sup.st day after the virus challenge, the CSFV challenge study ended at the 16.sup.th day after the virus challenge, and the PRV challenge study ended at the 14.sup.th day after the virus challenge. Clinical protective rates, morbidity, and mortality were calculated for each group of animals after the virus challenge study, and the results were shown in Table 12.

TABLE-US-00012 TABLE 12 Protective rates Virus challenge Batch Batch Batch Group Vaccine inoculation and dosage and dosage/pig No. 1 No. 2 No. 3 I 3-combo vaccine, 1 ml/pig: CSFV Shimen: 5/5 5/5 5/5 PRRSV TJM (10.sup.5.0 TCID.sub.50/ml) + 10.sup.6.0 MLD CSFV C strain (F16) (7500 RID, or 10.sup.4.0 FA-TCID.sub.50/ml) + PRV Bartha K61 (10.sup.5.5 TCID.sub.50/ml) II 3-combo vaccine, 1 ml/pig: PRRSV TJ, 4/5 4/5 5/5 PRRSV TJM (10.sup.5.0 TCID.sub.50/ml) + 2 .times. 10.sup.4.0-2 .times. 10.sup.4.5 CSFV C strain (F16) (7500 RID, or 10.sup.4.0 TCID.sub.50 FA-TCID.sub.50/ml) + PRV Bartha K61 (10.sup.5.5 TCID.sub.50/ml) III 3-combo vaccine, 1 ml/pig: PRV JL1: 5/5 4/5 5/5 PRRSV TJM (10.sup.5.0 TCID.sub.50/ml) + 10.sup.3.0-10.sup.3.5 TCID.sub.50 CSFV C strain (F16) (7500 RID, or 10.sup.4.0 FA-TCID.sub.50/ml) + PRV Bartha K61 (10.sup.5.5 TCID.sub.50/ml) IV CSFV C strain (F16), 1 ml/pig: CSFV Shimen: 5/5 5/5 5/5 7500 RID, or 10.sup.4.0 FA-TCID.sub.50/ml 10.sup.6.0 MLD V PRRSV TJM, 1 ml/pig: PRRSV TJ, 5/5 4/5 4/5 10.sup.5.0 TCID.sub.50/ml 2 .times. 10.sup.4.0-2 .times. 10.sup.4.5 TCID.sub.50 VI PRV Bartha K61, 1 ml/pig: PRV JL1: 4/5 4/5 5/5 10.sup.5.5 TCID.sub.50/ml 10.sup.3.0-10.sup.3.5 TCID.sub.50 VII PBS, 1 ml/pig CSFV Shimen: 0/3 0/3 0/3 10.sup.6.0 MLD VIII PBS, 1 ml/pig PRRSV TJ, 0/5 0/5 0/5 2 .times. 10.sup.4.0-2 .times. 10.sup.4.5 TCID.sub.50 IX PBS, 1 ml/pig PRV JL1: 0/5 0/5 0/5 10.sup.3.0-10.sup.3.5 TCID.sub.50 "RID": rabbit infective dose; "MLD": minimum lethal dose;

The three batches of the 3-combo vaccines of PRRSV, CSFV and PRV all demonstrated good protection against challenge from highly virulent PRRSV, CSFV or PRV, while the negative controls all showed evident clinical symptoms of infection. The protection from the 3-combo vaccine showed no significant difference from the single vaccine controls.

Example 19

Immuno-Duration Study for Combined PRRSV TJM Strain, CSFV C Strain and PRV Bartha K61 Strain

Immuno-duration study was carried out using three batches of the lab-made 3-combo vaccine (batch No.: 031-01, 031-02, and 031-03), prepared according to Example 6.

86 healthy pigs were used in the immuno-duration study. The pigs were negative for highly virulent PRRSV, CSFV and PRV, in terms of both antigen and antibody. The pigs were randomized into 9 groups, with 6 pigs in Group VII, and 10 pigs in each of the remaining groups. The pigs received vaccination or nothing according to the study design shown in Table 13. Blood samples were collected for determination of antibody titers at 1.sup.st, 2.sup.nd, 3.sup.rd, 4.sup.th, 5.sup.th, or 6.sup.th month post vaccination.

At 3 months and 6 months post vaccination, respectively, half of the animals were taken from each study group and were challenged with the respective virulent virus, as shown in Table 13.

TABLE-US-00013 TABLE 13 Virus challenge and Protective rates Group Vaccine inoculation and dosage dosage/pig 3-mon 6-mon I 3-combo vaccine, 1 ml/pig: CSFV Shimen: 5/5 5/5 PRRSV TJM (10.sup.5.0 TCID.sub.50/ml) + 10.sup.6.0 MLD CSFV C strain (F16) (7500 RID, or 10.sup.4.0 FA-TCID.sub.50/ml) + PRV Bartha K61 (10.sup.5.5 TCID.sub.50/ml) II 3-combo vaccine, 1 ml/pig: PRRSV TJ, 5/5 5/5 PRRSV TJM (10.sup.5.0 TCID.sub.50/ml) + 2 .times. 10.sup.4.0-2 .times. 10.sup.4.5 CSFV C strain (F16) (7500 RID, or 10.sup.4.0 TCID.sub.50 FA-TCID.sub.50/ml) + PRV Bartha K61 (10.sup.5.5 TCID.sub.50/ml) III 3-combo vaccine, 1 ml/pig: PRV JL1: 5/5 5/5 PRRSV TJM (10.sup.5.0 TCID.sub.50/ml) + 10.sup.3.0-10.sup.3.5 TCID.sub.50 CSFV C strain (F16) (7500 RID, or 10.sup.4.0 FA-TCID.sub.50/ml) + PRV Bartha K61 (10.sup.5.5 TCID.sub.50/ml) IV CSFV C strain (F16), 1 ml/pig: CSFV Shimen: 5/5 5/5 7500 RID, or 10.sup.4.0 FA-TCID.sub.50/ml 10.sup.6.0 MLD V PRRSV TJM, 1 ml/pig: PRRSV TJ, 4/5 4/5 10.sup.5.0 TCID.sub.50/ml 2 .times. 10.sup.4.0-2 .times. 10.sup.4.5 TCID.sub.50 VI PRV Bartha K61, 1 ml/pig: PRV JL1: 4/5 4/5 10.sup.5.5 TCID.sub.50/ml 10.sup.3.0-10.sup.3.5 TCID.sub.50 VII PBS, 1 ml/pig CSFV Shimen: 0/3 0/3 10.sup.6.0 MLD VIII PBS, 1 ml/pig PRRSV TJ, 0/5 0/5 2 .times. 10.sup.4.0-2 .times. 10.sup.4.5 TCID.sub.50 IX PBS, 1 ml/pig PRV JL1: 0/5 0/5 10.sup.3.0-10.sup.3.5 TCID.sub.50 "RID": rabbit infective dose; "MLD": minimum lethal dose;

Results showed that (see Table 13), the 3-combo vaccines provided effective protection to pigs against virus challenge 6 months after the vaccination, and therefore supported a 6-month immuno-duration period. The immuno-duration of the 3-combo vaccines was found comparable to each of the single vaccines.

Part III

Safety Studies

Example 20

Safety Study of the Combined PRRSV and CSFV Vaccine

Safety study was carried out using three batches of the lab-made 2-combo vaccine for PRRSV and CSFV (batch No.: 200904, 200905, and 200906), as prepared according to Example 4.

The study included a single dose safety study, repetitive dose safety study, over-dose safety study on target age pigs, over-dose safety study on under-age pigs, and over-dose safety study on pigs of different breeds.

The results showed, after vaccination, pigs in each study group showed normal temperature, were in good spirits and good appetites. No systemic or local adverse effects were observed. Over-dose administration of the combination vaccines was shown to be safe to under-age pigs, and also to pigs of different breeds.

Example 21

Safety Study of the Combined PRRSV and PRV Vaccine

Safety study was carried out using three batches of the 2-combo vaccine of PRRSV and PRV, as prepared according to Example 5.

Pigs aged 4-5 weeks, negative for both PRRS and PR, in terms of both antigen and antibody, were randomized in 3 groups, with 15 pigs in each group. Each group was inoculated with the 2-combo vaccine in a single dose (10.sup.5.0-10.sup.5.5 TCID.sub.50 virus/ml), repetitive doses or a 10-fold over-dose. 5 pigs were used as a control group and were not inoculated at all.

Rectal temperatures of the pigs were taken each day, until the 21.sup.st day after the vaccination. The pigs were also under close clinical observation.

The results showed that pigs in each group showed normal temperature and no pathological changes after vaccination. The 2-combo vaccine was safe to pigs.

Example 22

Safety Study of the Combined PRRSV, CSFV and PRV Vaccine

Safety study was carried out using three batches of the lab-made 3-combo vaccine for PRRSV, CSFV and PRV (batch No.: 031-01, 031-02, and 031-03), as prepared according to Example 6. The study included a single dose safety study, repetitive dose safety study, over-dose safety study on target age pigs, over-dose safety study on under-age pigs, and over-dose safety study on pigs of different breeds.

The results showed, after vaccination, pigs in each study group showed normal temperature, were in good spirits and good appetites. No systemic or local adverse effects were observed. Over-dose administration of the combination vaccine was shown to be safe to under-age pigs, and also to pigs of different breeds.

Part IV

Stability Studies

Example 23

Stability Study of the 2-Combo Vaccine for PRRSV and CSFV

The lab-made combined PRRSV and CSFV vaccines (batch Nos.: 200904, 200905, and 200906) were tested for stability, and compared in parallel with three batches of PRRSV single vaccine and CSFV single vaccine (batch Nos.: 200901, 200902, 200903, 200907, 200908, and 200909).

The three batches of each of the vaccine composition were kept at 2-8.degree. C. Samples were collected at 3, 6, 9, 12, and 18 months of the study, respectively. The samples were tested for physiochemical properties, vacuum degree, residual water content, potency, and aging at 37.degree. C.

After 18-month storage at 2-8.degree. C., the three batches of the 2-combo vaccine compositions were in white loosen clumps, which were rapidly dissolved upon addition of a diluting buffer. In the test of degree of vacuum, the vaccines showed white or purple glow. The average residual water content of the tested vaccines met the requirements set by Chinese Veterinary Pharmacopoeia.

The virus titers of the vaccine compositions were determined, and the results were shown in FIGS. 27-30. After storage at 2-8.degree. C. for 18 months, the virus titers of the 2-combo vaccine were not significantly different from that of each single vaccine. After being kept at 37.degree. C. for 14 days, the 2-combo vaccines still contained high level of virus titers, which were not significantly different from each of the single vaccine in the parallel studies. The virus titers of the vaccine compositions met the requirement for a qualified vaccine. This showed that the heat-resistant cryoprotectant provided good protection to the PRRSV vaccine strain and the CSFV vaccine strain during the freeze-drying procedures.

As is known in the art, conventional vaccines are usually kept under 0.degree. C. (-20.degree. C.), which complicates the storage of the vaccines. The results of this Example showed that, with the new cryoprotectant, the vaccine compositions can be shipped and stored at a higher temperature, thereby providing a higher stability of the vaccines.

Example 24

Stability Study of the 2-Combo Vaccine for PRRSV and PRV

The three batches of lab-made 2-combo vaccines for PRRSV and PRV were kept at 2-8.degree. C. Samples were collected at 3rd, 6th, 9th, 12th, 18th, 21st and 24th months of the study, respectively. The samples were tested for physiochemical properties, vacuum degree, residual water content, potency, and aging at 37.degree. C.

After 24-month storage at 2-8.degree. C., the three batches of the vaccine compositions were in white loosen clumps, which were rapidly dissolved upon addition of a diluting buffer. In the test of degree of vacuum, the vaccines showed white or purple glow. The virus titers of the vaccine compositions were determined, and the results were shown in FIGS. 31-34. The combined vaccines were stable after storage at 2-8.degree. C. for 24 months, and the virus titers were not significantly different from those before the storage.

Example 25

Stability Study of the 3-Combo Vaccine for PRRSV, CSFV and PRV

The lab-made 3-combo vaccines for PRRSV, CSFV and PRV (batch Nos.: 031-01, 031-02, and 031-03) were tested for stability, and compared in parallel with three batches of PRRSV single vaccine (batch Nos.: 031-04, 031-05, 031-06), CSFV single vaccine (batch Nos.: 031-07, 031-08, 031-09) and PRV single vaccine (batch Nos.: 031-10, 031-11 and 031-12).

The vaccine compositions were kept at 2-8.degree. C. Samples were collected at the 3rd, 6th, 9th, 12th, and 18th month of the study, respectively. The samples were tested for physiochemical properties, vacuum degree, residual water content, potency, and aging at 37.degree. C.

After 18-month storage at 2-8.degree. C., the three batches of the vaccine compositions were in white loosen clumps, which were rapidly dissolved upon addition of a diluting buffer. In the test of degree of vacuum, the vaccines showed white or purple glow. The average residual water content of the tested vaccines met the requirements set by Chinese Veterinary Pharmacopoeia.

The virus titers of the vaccine compositions were determined, and the results were shown in FIGS. 35-40. After storage at 2-8.degree. C. for 18 months, the virus titers of the combined vaccines were not significantly different from that of the single vaccines. After being kept at 37.degree. C. for 14 days, the combined vaccines still showed high level of virus titer, which was not significantly different from that of the single vaccines under the parallel studies. This demonstrated that, the heat-resistant cryoprotectant provided good protection to the PRRSV vaccine strain, the CSFV vaccine strain and the PRV vaccine strain during the freeze-drying procedures.

SEQUENCE LISTINGS

1

1111149DNAPorcine reproductive and respiratory syndrome virus 1atgtctggga tacttgatcg gtgcacgtgt acccccaatg ccagggtgtt tgtggcggag 60ggccaggtct actgcacacg atgtctcagt gcacggtctc tccttcctct gaatctccaa 120gttcctgagc ttggggtgct gggtctattc tataggcccg aagagccact ccggtggacg 180ttgccacgtg cattccccac tgtcgagtgc tcccccgccg gggcctgctg gctttctgcg 240atctttccga ttgcacgaat gactagtgga aacctgaact ttcaacaaag aatggtgcgg 300gtcgcagctg aaatctacag agccggccaa ctcaccccta cagttctaaa gactctacaa 360gtttatgaac ggggttgtcg ctggtacccc attgtcgggc ccgtccctgg ggtgggcgtt 420tacgccaact ccctgcatgt gagtgacaaa cctttcccgg gagcaactca tgtgttaacc 480aacttgccgc tcccgcagag gcccaaacct gaggactttt gcccttttga gtgtgctatg 540gctgacgtct atgacattgg tcgtggcgcc gtcatgtatg tggccggagg aaaggtctct 600tgggcccctc gtggtgggaa tgaagtgaaa tttgaacctg tccccaagga gttgaagttg 660gttgcgaacc gactccacac ctccttcccg ccccatcacg tagtggacat gtccaggttt 720accttcatga cccctgggag tggtgtctcc atgcgggttg agtaccaata cggctgcctc 780cccgctgaca ctgtccctga aggaaactgc tggtggcgct tgtttgactc gctcccaccg 840gaagttcagt acaaagaaat tcgccacgct aaccaatttg gctatcaaac caagcatggt 900gtccctggca agtacctaca gcggaggctg caagttaatg gtcttcggac agtgaccgac 960acacatggac ctatcgtcat acagtacttc tctgttaagg agagttggat ccgccacctg 1020aagttggtgg aagaacccag cctccccggg tttgaggatc tcctcagaat cagggttgag 1080cccaatacgt caccactggc tggaaaggat gagaagattt tccggtttgg cagtcataag 1140tggtacggt 114922490DNAPorcine reproductive and respiratory syndrome virus 2gccggaaaga gagcaaggaa aacacgctct ggtgcgacta ctatggtcgc tcatcacgct 60tcgtccgctc ataaaatccg gcaggccacg aagcacgagg gtgccggcgc taacaaggct 120gagcatctca agcgctactc tccgcctgcc gaagggaact gtggttggca ctgcatttcc 180gccatcgcca accggatggt gaattccaac tttgagacca cccttcctga aagagtaagg 240ccttcagatg actgggccac tgacgaggat cttgtgaata ccatccaaat cctcaggctc 300cctgcggcct tggacaggaa cggcgcttgc ggtagcgcca agtacgtgct taaactggag 360ggtgagcatt ggactgtctc tgtgatccct gggatgtccc ctactttgct cccccttgaa 420tgtgttcagg gttgttgtga acataagggc ggtcttgttt ccccggatgc ggtcgaaatt 480tccggatttg atcctgcctg ccttgaccga ctggctaagg taatgcactt gcctagcagt 540accatcccag ccgctctggc cgaattgtcc gacgactcca accgtccggt ttccccggcc 600gctactacgt ggactgtttc gcaattctat gctcgtcata gaggaggaga tcatcatgac 660caggtgtgct tagggaaaat catcagcctt tgtcaagtta ttgaggactg ctgctgccat 720cagaataaaa ccaaccgggc tactccggaa gaggtcgcgg caaagattga tcagtacctc 780cgtgacgcaa caagtcttga ggaatgcttg gccaaacttg agagagtttc cccgccgagc 840gcagcggaca cctcctttga ttggaatgtt gtgcttcctg gggttgaggc gacgaatcag 900acaaccgaac aacctcacgt caactcatgc tgcaccccgg tccctcccgt gactcaagag 960cctttgggcg aggactcggt ccctctgacc gccttctcac tgtccaattg ctattaccct 1020gcacaaggtg acgaggttca tcaccgtgag aggttaaatt ccgcactctc taagttggaa 1080gaggttgtcc tggaagaata tgggctcatg tccactggac ttggcccgcg acccgtgctg 1140ccgagcgggc tcgacgagct taaagaccag atggaggagg atctgctaga actagccaac 1200acccaggcga cttcagaaat gatggcctgg gcggctgagc aggtcgattt aaaagcttgg 1260gtcaaaagct acccgcggtg gacaccacca ccccctccac caagagttca acctcgaaga 1320acaaagtctg tcaaaagttt gccagaggac aagcctgtcc ctgctccgcg caggaaggtc 1380agatccgatt gcggcagccc ggttttgatg ggcgacaatg tccctaacgg ttcggaagaa 1440actgtcggtg gtctcctcaa ttttccgaca ccatccgagc cgatgacacc tatgagtgag 1500cccgtacttg tgcccgcgtc gcgacgtgtc cccaagctga tgacaccttt gagtgggtcg 1560gcaccagttc ctgcaccgcg tagaactgtg acaacaacgc tgacgcacca ggatgagcct 1620ctggatttgt ctgcgtcctc acaaacggaa tatgaggctt cccccctaac accatcgcag 1680aacatgggca tcctggaggc gggggggcaa gaagctgagg gagtcctgag tgaaatctcg 1740gatatactaa atgacaccaa ccctgcacct gtgtcatcaa gcagctccct gggttcagtg 1800gccaccgagg atgttccacg catcctcggg aaaataggag acactgacga gctgcttgac 1860cggggtccct cggcaccctc caagggagaa ccggtctgtg accaacctgc caaagatccc 1920cggatgtcgc cgcgggagtc tgacgagagc ataatagttc cgcccgcaga tacaggtggt 1980gtcggctcat tcactgattt gccgtcttca gatggtgtgg atgtggacgg gggggggccg 2040ttaagaacgg taaaaacaaa agcagaaagg ctcttagatc aactgagctg ccaggttttt 2100agcctcgttt cccatctccc tattttcttc tcacacctct tcaaatctga cagtggttat 2160tctccgggtg attggggttt tgcagctttt actctatttt gcctcttttt atgttacagt 2220tacccattct tcggttttgc tcccctcttg ggtgtatttt ctgggtcttc tcggcgtgtg 2280cgaatggggg tttttggctg ctggttggct tttgctgttg gtctgttcaa gcctgtgtcc 2340gacccagtcg gcactgcttg tgagtttgac tcgccagagt gtaggaacgt ccttcattct 2400tttgagcttc tcaaaccttg ggaccctgtc cgcagccttg ttgtgggccc cgtcggtctc 2460ggccttgcca ttcttggcag gttactgggc 2490314966DNAPorcine reproductive and respiratory syndrome virus 3atgacgtata ggtgttggct ctatgccacg gcatttgtat tgtcaggagc tgtgaccata 60ggcacagccc aaaacttgct gcacgggaac accctcctgt gacagccctc ttcaggggga 120ttaggggtct gtccctaaca ccttgcttcc ggagttgcac tgctttacgg tctctccacc 180cctttaacca tgtctgggat acttgatcgg tgcacgtgta cccccaatgc cagggtgttt 240gtggcggagg gccaggtcta ctgcacacga tgtctcagtg cacggtctct ccttcctctg 300aatctccaag ttcctgagct tggggtgctg ggtctattct ataggcccga agagccactc 360cggtggacgt tgccacgtgc attccccact gtcgagtgct cccccgccgg ggcctgctgg 420ctttctgcga tctttccgat tgcacgaatg actagtggaa acctgaactt tcaacaaaga 480atggtgcggg tcgcagctga aatctacaga gccggccaac tcacccctac agttctaaag 540actctacaag tttatgaacg gggttgtcgc tggtacccca ttgtcgggcc cgtccctggg 600gtgggcgttt acgccaactc cctgcatgtg agtgacaaac ctttcccggg agcaactcat 660gtgttaacca acttgccgct cccgcagagg cccaaacctg aggacttttg cccttttgag 720tgtgctatgg ctgacgtcta tgacattggt cgtggcgccg tcatgtatgt ggccggagga 780aaggtctctt gggcccctcg tggtgggaat gaagtgaaat ttgaacctgt ccccaaggag 840ttgaagttgg ttgcgaaccg actccacacc tccttcccgc cccatcacgt agtggacatg 900tccaggttta ccttcatgac ccctgggagt ggtgtctcca tgcgggttga gtaccaatac 960ggctgcctcc ccgctgacac tgtccctgaa ggaaactgct ggtggcgctt gtttgactcg 1020ctcccaccgg aagttcagta caaagaaatt cgccacgcta accaatttgg ctatcaaacc 1080aagcatggtg tccctggcaa gtacctacag cggaggctgc aagttaatgg tcttcggaca 1140gtgaccgaca cacatggacc tatcgtcata cagtacttct ctgttaagga gagttggatc 1200cgccacctga agttggtgga agaacccagc ctccccgggt ttgaggatct cctcagaatc 1260agggttgagc ccaatacgtc accactggct ggaaaggatg agaagatttt ccggtttggc 1320agtcataagt ggtacggtgc cggaaagaga gcaaggaaaa cacgctctgg tgcgactact 1380atggtcgctc atcacgcttc gtccgctcat aaaatccggc aggccacgaa gcacgagggt 1440gccggcgcta acaaggctga gcatctcaag cgctactctc cgcctgccga agggaactgt 1500ggttggcact gcatttccgc catcgccaac cggatggtga attccaactt tgagaccacc 1560cttcctgaaa gagtaaggcc ttcagatgac tgggccactg acgaggatct tgtgaatacc 1620atccaaatcc tcaggctccc tgcggccttg gacaggaacg gcgcttgcgg tagcgccaag 1680tacgtgctta aactggaggg tgagcattgg actgtctctg tgatccctgg gatgtcccct 1740actttgctcc cccttgaatg tgttcagggt tgttgtgaac ataagggcgg tcttgtttcc 1800ccggatgcgg tcgaaatttc cggatttgat cctgcctgcc ttgaccgact ggctaaggta 1860atgcacttgc ctagcagtac catcccagcc gctctggccg aattgtccga cgactccaac 1920cgtccggttt ccccggccgc tactacgtgg actgtttcgc aattctatgc tcgtcataga 1980ggaggagatc atcatgacca ggtgtgctta gggaaaatca tcagcctttg tcaagttatt 2040gaggactgct gctgccatca gaataaaacc aaccgggcta ctccggaaga ggtcgcggca 2100aagattgatc agtacctccg tgacgcaaca agtcttgagg aatgcttggc caaacttgag 2160agagtttccc cgccgagcgc agcggacacc tcctttgatt ggaatgttgt gcttcctggg 2220gttgaggcga cgaatcagac aaccgaacaa cctcacgtca actcatgctg caccccggtc 2280cctcccgtga ctcaagagcc tttgggcgag gactcggtcc ctctgaccgc cttctcactg 2340tccaattgct attaccctgc acaaggtgac gaggttcatc accgtgagag gttaaattcc 2400gcactctcta agttggaaga ggttgtcctg gaagaatatg ggctcatgtc cactggactt 2460ggcccgcgac ccgtgctgcc gagcgggctc gacgagctta aagaccagat ggaggaggat 2520ctgctagaac tagccaacac ccaggcgact tcagaaatga tggcctgggc ggctgagcag 2580gtcgatttaa aagcttgggt caaaagctac ccgcggtgga caccaccacc ccctccacca 2640agagttcaac ctcgaagaac aaagtctgtc aaaagtttgc cagaggacaa gcctgtccct 2700gctccgcgca ggaaggtcag atccgattgc ggcagcccgg ttttgatggg cgacaatgtc 2760cctaacggtt cggaagaaac tgtcggtggt ctcctcaatt ttccgacacc atccgagccg 2820atgacaccta tgagtgagcc cgtacttgtg cccgcgtcgc gacgtgtccc caagctgatg 2880acacctttga gtgggtcggc accagttcct gcaccgcgta gaactgtgac aacaacgctg 2940acgcaccagg atgagcctct ggatttgtct gcgtcctcac aaacggaata tgaggcttcc 3000cccctaacac catcgcagaa catgggcatc ctggaggcgg gggggcaaga agctgaggga 3060gtcctgagtg aaatctcgga tatactaaat gacaccaacc ctgcacctgt gtcatcaagc 3120agctccctgg gttcagtggc caccgaggat gttccacgca tcctcgggaa aataggagac 3180actgacgagc tgcttgaccg gggtccctcg gcaccctcca agggagaacc ggtctgtgac 3240caacctgcca aagatccccg gatgtcgccg cgggagtctg acgagagcat aatagttccg 3300cccgcagata caggtggtgt cggctcattc actgatttgc cgtcttcaga tggtgtggat 3360gtggacgggg gggggccgtt aagaacggta aaaacaaaag cagaaaggct cttagatcaa 3420ctgagctgcc aggtttttag cctcgtttcc catctcccta ttttcttctc acacctcttc 3480aaatctgaca gtggttattc tccgggtgat tggggttttg cagcttttac tctattttgc 3540ctctttttat gttacagtta cccattcttc ggttttgctc ccctcttggg tgtattttct 3600gggtcttctc ggcgtgtgcg aatgggggtt tttggctgct ggttggcttt tgctgttggt 3660ctgttcaagc ctgtgtccga cccagtcggc actgcttgtg agtttgactc gccagagtgt 3720aggaacgtcc ttcattcttt tgagcttctc aaaccttggg accctgtccg cagccttgtt 3780gtgggccccg tcggtctcgg ccttgccatt cttggcaggt tactgggcgg ggcacgctac 3840atctggcact ttttgcttag gcttggcatt gttgcagact gtgtcttggc tggagcttat 3900gtgctttctc aaggtaggtg taaaaagtgc tggggatctt gtgtaagaac tgctcctaat 3960gagatcgcct tcaacgtgtt cccttttaca cgtgcgacca ggtcgtcact catcgacctg 4020tgcgatcggt tttgcgcacc aaaaggcatg gaccccattt ttctcgccac tgggtggcgt 4080gggtgctgga ccggccggag tcccattgag caaccttctg aaaaacccat cgcgttcgcc 4140cagctggatg agaagaggat tacggctaga actgtggtcg ctcagcctta tgatcccaac 4200caggccgtaa agtgcttgcg ggtattacag gcgggtgggg cgatggtggc cgaggcagtc 4260ccaaaagtgg tcaaagtttc cgctattcca ttccgagctc ctttctttcc cgctggagtg 4320aaagttgatc ctgagtgcag aatcgtggtt gatcccgata cttttactac agccctccgg 4380tctggctatt ccaccgcgaa cctcgtcctt ggtacggggg actttgccca gctgaatgga 4440ctaaagatca ggcaaatttc caagccttca gggggaggcc cacacctcat tgctgccttg 4500catgttgcct gctcgatggc gttacacatg cttgctggtg tttatgtaac tgcagtgggg 4560tcctgcggtg ccggtaccaa cgatccgtgg tgcactaacc cgtttgctgt ccctggctat 4620ggacctggct ctctttgcac gtctagattg tgcatctccc aacacggcct caccttgccc 4680ttgacagcac ttgtggcggg attcggcctt caagagattg ccttggtcgt tttgatcttt 4740gtctccatcg gaggcatggc tcataggttg agttgtaagg ctgacatgtt gtgcatctta 4800ctcgcaatcg ctagttatgt ttgggtacct cttacctggt tgctttgtgt gtttccttgt 4860tggttgcgct ggtcctcttt gcaccccctc accatcctgt ggttggtgtt tttcttgatt 4920tctgtaaata taccctcggg aatcttggcc gtggtgttat tggtttctct ctggctttta 4980ggtcgttata ctaacattgc tggtctcgtc accccttatg acattcatca ttacaccagt 5040ggcccccgcg gtgtcgccgc cttggccacc gcgccagatg gaacctactt ggctgccgtc 5100cgccgtgctg cgctgactgg tcgtaccatg ctgttcaccc cgtctcagct tgggtccctc 5160cttgagggcg ctttcagaac tcaaaaaccc tcactgaaca ccgtcaatgt ggtcgggtcc 5220tccatgggct ctggcggagt gttcactatt gacgggaaaa tcaagtgcgt gactgccgca 5280catgtcctta cgggtaactc agctagggtt tccggggtcg gcttcaatca aatgcttgac 5340tttgatgtaa aaggggactt cgccatagct gattgcccga attggcaagg ggttgctccc 5400aaggcccagt tctgcgagga tgggtggact ggtcgcgcct attggctgac atcctctggc 5460gttgaacccg gtgttattgg gaatgggttc gccttctgct tcaccgcgtg tggcgattct 5520ggatccccag tgattaccga agccggtgag cttgtcggcg ttcacacagg atcaaacaaa 5580caaggaggag gcattgtcac gcgcccctca ggccagtttt gtaatgtgaa gcccatcaag 5640ctgagcgagt tgagtgaatt cttcgctgga cctaaggtcc cgctcggtga tgtgaaaatt 5700ggcagtcaca taattaatga cacatgcgag gtgccttcag atctttgtgc cctgcttgct 5760gccaaacccg aactggaagg aggcctttcc acagttcaac ttctgtgtgt gtttttcctc 5820ctgtggagaa tgatggggca tgcctggacg cccttggttg ctgtggggtt tttcatcctg 5880aatgagattc tcccagctgt tctggtccgg agtgttttct cctttgggat gtttgtgcta 5940tcttggctca caccatggtc tgcgcaagtc ctgatgatca ggcttctgac agcagccctt 6000aacagaaaca gatggtctct tggtttttac agccttggtg caataaccag ttttgtcgca 6060gatcttgcgg taactcaagg gcatccgtta caggtggtaa tgaacttaag cacctatgcc 6120ttcctgcccc ggatgatggt tgtgacctcg ccagtcccag tgatcgcgtg tggtgttgtg 6180cacctccttg ccataatttt gtacttgttt aagtaccgct gccttcacaa tgtccttgtt 6240ggcgatgggg tgttctcttc ggctttcttc ttgcgatact ttgccgaggg aaagttgagg 6300gaaggggtgt cgcaatcctg tgggatgagt catgagtcgc tgactggtgc cctcgccatg 6360agactcactg acgaggactt ggatttcctt acgaaatgga ctgattttaa gtgctttgtt 6420tctgcgtcca acatgaggaa tgcagcgggc caatttatcg aggctgctta tgcaaaagca 6480ctaagaattg aacttgctca gttggtacag gttgataagg tccgaggcac catggccaaa 6540ctcgaggctt tcgccgatac cgtggcaccc caactctcgc ccggtgacat tgttgttgcc 6600cttggccaca cgcctgttgg cagcatcttc gacctaaagg ttggtagcac caagcatact 6660ctccaagcta ttgagactag agtccttgcc gggtccaaaa tgactgtggc gcgtgtcgtt 6720gacccaaccc ccgcaccccc gcccgtacct gtgcccatcc ctctcccacc gaaagttctg 6780gagaacggtc ccaatgcctg gggggatgag gaccgtttga acaagaagaa gaggcgcagg 6840atggaagccg tcggcatttt tgtcatggac gggaaaaagt accagaaatt ttgggacaag 6900aattccggtg atgtgtttta tgaggaggtc catattagca cagacgagtg ggagtgcctt 6960agaactggcg accctgtcga ctttgatcct gagacaggga ttcagtgtgg gcatatcacc 7020attgaagata aggtttacaa tgtcttcacc tccccatctg gtaggagatt cttggtcccc 7080gccaaccccg agaatagaag agctcagtgg gaagccgcca agctttccgt ggagcaagcc 7140cttggtatga tgaacgtcga cggcgaactg actgccaaag aactggagaa actgaaaaga 7200ataattgaca aactccaggg cctgactaag gagcagtgtt taaactgcta gccgccagcg 7260gcctgacccg ctgtggtcgc ggcggcttag ttgttactga gacagcggta aaaatagtca 7320aatttcacaa ccggaccttc accccaggac ctgtgaactt aaaagtggcc agtgaggttg 7380agctaaaaga cgcggttgag cacaaccaac atccggttgc cagaccggtt gatggtggtg 7440tcgtgctcct gcgctctgca gttccttcgc ttatagatgt cttgatctcc ggcgctgata 7500catctcctaa gttactcgcc cgccacgggc cgggaaacac tgggattgat ggcacgcttt 7560gggattttga ggccgaggct actaaagagg aagttgcact cagtgcgcaa ataatacagg 7620cttgtgatat taggcgcggc gacgcacctg aaattggtct cccttataag ttgtaccctg 7680ttaggggcaa ccctgagcgg gtaaaaggag ttttacagaa tacaaggttt ggagacatac 7740cttacaaaac ccccagtgac actggaagcc cggtgcacgc ggctgcctgc ctcacgccta 7800atgctactcc ggtgactgat gggcgctccg tcttggctac aaccatgccc tctggctttg 7860agttgtatgt gccgaccatt ccagcgtccg tccttgatta tcttgattct aggcctgact 7920gccctaaaca gttaacagag cacggttgtg aggatgctgc attaagagac ctctccaagt 7980atgatttgtc cacccaaggc tttgttttgc ctggagttct tcgccttgtg cggaagtacc 8040tgttcgccca cgtgggtaag tgcccgcccg ttcatcggcc ttccacttac cctgctaaga 8100attctatggc tggaataaat gggaacaggt ttccaaccaa ggacattcag agcgtccctg 8160aaatcgacgt tctgtgcgca caggctgtgc gagaaaactg gcaaactgtt accccttgta 8220ccctcaagaa acagtactgt gggaagaaga agactaggac aatacttggc accaataact 8280tcattgcgtt ggcccatcgg gcagcgttga gtggtgttac ccagggcttc atgaaaaaag 8340cgttcaactc gcccatcgcc ctcgggaaaa acaaatttaa ggagctacaa gccccggtcc 8400taggcaggtg ccttgaagct gatcttgcgt cctgcgatcg atccacacct gcaattgtcc 8460gctggtttgc cgccaatctt ctttatgaac tcgcctgtgc tgaggagcat ctaccgtcgt 8520acgtgctgaa ctgctgccac gacttactgg tcacgcagtc cggcgcggtg actaagagag 8580gtggcctgtc gtctggcgac ccgattacct ctgtgtcaaa caccatttac agcttagtga 8640tatatgcaca gcacatggtg ctcagttact tcaaaagtgc tcaccctcat ggccttctgt 8700ttctgcaaga ccagctgaag tttgaggaca tgctcaaggt tcaacccctg accgtctatt 8760cggacgacct tgtgctgtat gccgagtctc cctccatgcc aaactaccac tggtgggttg 8820aacatctgaa ccttatgctg ggtttccaga cggacccaaa gaagacaacc atcacagact 8880caccatcatt cctaggttgc aggataataa atgggcgcca gctggtccct aaccgtgaca 8940ggatcctcgc ggccctcgcc taccacatga aggcgagcaa tgtttctgaa tactacgcct 9000cggcggctgc aatactcatg gacagctgtg cttgtttgga gtatgatcct gaatggtttg 9060aagagctcgt ggttgggata gcgcagtgcg cccgcaagga cggctacagc tttcctggcc 9120caccgttctt cttgtccatg tgggaaaaac tcaggtccaa tcatgagggg aagaagtcca 9180gaatgtgcgg gtactgcggg gccccggctc cgtacgccac tgcctgtggt ctcgatgtct 9240gtgtttacca cacccacttc caccagcatt gtcctgttat aatctggtgt ggccacccgg 9300cgggttctgg ttcttgtagt gagtgcgaac cccccctagg aaaaggcaca agccctctag 9360atgaggtgtt agaacaagtt ccgtacaagc ctccgcggac tgtgatcatg catgtggagc 9420agggtctcac ccctcttgac ccaggtagat accagactcg ccgcggattg gtctccgtta 9480ggcgtggcat caggggaaat gaagtcgacc taccagacgg tgattacgcc agtaccgcct 9540tgctccctac ttgtaaagag atcaacatgg tcgctgtcgc ctctaacgtg ttgcgcagca 9600ggtttatcat cggcccaccc ggtgctggga aaacacactg gcttcttcaa caagtccagg 9660atggtgatgt catttacacg ccaactcacc agaccatgct cgacatgatt agggctttgg 9720ggacgtgccg gttcaacgtt ccagcaggta caacgctgca attccctgcc ccctcccgta 9780ccggcccatg ggttcgcatc ttggccggcg gttggtgtcc tggcaagaac tccttcctgg 9840atgaagcggc gtattgcaat caccttgacg tcttgaggct tctcagtaaa acaactctca 9900cttgcctagg ggacttcaaa caactccacc ctgtgggttt tgactcccat tgctatgtat 9960ttgacatcat gcctcagacc caattaaaga ccatctggag gttcgggcag aatatctgtg 10020atgccattca accagattac agggacaaac ttatggccat ggtcaacacg acccgtgtga 10080cctacgtgga aaaacctgtc aggtacgggc aagtcctcac cccctaccac agggaccgag 10140aggacggcgc cattactatc gactccagtc aaggcgccac atttgatgtg gttacactgc 10200atttgcccac taaagattca ctcaacaggc aaagagctct tgttgctatc accagggcaa 10260ggcatgctat cttcgtgtat gacccacaca ggcaattgca gagcatgttt gatcttcccg 10320cgagaggcac acccgtcaac ctcgcagtgc accgtgacga acagctgatc gtattagaca 10380gaaacaacag agaaatcacg gttgctcagg ctctaggcaa tggagataaa ttcagggcca 10440cagataagcg cgttgtagat tctctccgcg ctatttgcgc agacctggaa gggtcgagct 10500ccccgctccc caaggtcgcg cataacttgg gattccattt ctcacctgat ttgactcagt 10560ttgctaaact cccggcagaa cttgcacccc actggcccgt ggtgacaacc cagaacaatg 10620aaaggtggcc agatcggctg gtagccagcc tccgccctat ccataaatat agccgcgcgt 10680gcattggtgc cggctatatg gtgggcccct cggtgttttt aggcacccct ggggttgtgt 10740catactatct cacaaaattt gttagaggcg aggctcaagt gcttccggag acagtcttca 10800gcaccggccg aattgaggta gattgtcgag agtatcttga tgatcgggag cgagaagttg 10860ctgagtccct cccacatgcc ttcatcggcg atgtcaaagg taccaccgtt gggggatgtc 10920atcacgttac ctccaaatac cttccgcgct tccttcccaa ggaatcagtt gcggtggtcg 10980gggtttcgag ccccgggaaa gccgcgaaag cagtttgcac attgacggat gtgtacctcc 11040cagaccttga agcgtacctc cacccagaga cccagtccag gtgctggaaa gtgatgttgg 11100actttaagga ggttcgactg atggtatgga aagacaagac ggcctatttt caacttgaag

11160gccgccattt tacctggtat caacttgcaa gctacgcctc atacatccga gttcctgtta 11220attctactgt gtacttggac ccctgcatgg gccctgctct ttgcaacagg agggttgtcg 11280ggtccaccca ttggggagct gacctcgcag tcacccctta tgattacggt gccaaaatta 11340ttctgtctag tgcataccat ggtgaaatgc ctccaggtta caaaattctg gcgtgcgcgg 11400agttctcgct tgatgatcca gtaaggtaca aacacacctg gggatttgaa tcggatacag 11460cgtatctgta cgagtttact ggaaatggtg aggactggga ggattacaat gatgcgtttc 11520gggcgcgcca gaaagggaaa atttataaag ctaatgccac cagcatgagg tttcattttc 11580ccccgggccc tgtcattgaa ccaactttag gcctgaattg aaatgaaatg gggtctatgc 11640aaagcctctt tgacaaaatt ggccaacttt ttgtggatgc tttcacggaa tttctggtgt 11700ccattgttga tatcatcata tttttggcca ttttgtttgg cttcacaatc gccggttggc 11760tggtggtctt atgcatcaga ctggtttgct ccgcggtact ccgtgcgcgc tctaccgttc 11820accctgagca attacagaag atcttatgag gcctttcttt ctcagtgtca ggtagacatt 11880cccacctggg gcgtcaaaca ccctttgggg gtgctttggc accataaggt gtcaaccctg 11940attgatgaaa tggtgtcgcg tcgaatgtac cgcgtcatgg aaaaagcagg gcaggctgcc 12000tggaaacagg tggtgagcga ggctacattg tctcgcatta gtggtttgga tgtggtggct 12060cattttcaac atcttgccgc tattgaagcc gagacttgta aatatttggc ttcccggcta 12120cccatgctgc acaacctgcg cttgacaggg tcaaatgtaa ccatagtgta taatagtact 12180ttggatcagg tgtttgccat tttcccaacc cctggttccc ggccaaagct tcatgatttt 12240cagcaatggc taatagctgt acattcctcc atattttcct ccgttgcagc ttcttgtact 12300ctttttgttg tgctgtggtt gcgaattcca atgctacgtt ctgtttttgg tttccgctgg 12360ttaggggcaa cttttctttt gaactcatgg tgaattacac ggtatgcccg ctttgcccaa 12420cccggcaggc agccgccgag atccttgaac ccggcaagtc tttttggtgc aggatagggc 12480atgaccgatg tagtgagaac gatcatgacg aactagggtt catggttccg cctggcctct 12540ccagcgaagg ccacttgacc agtgtttacg cctggttggc gttcctgtcc ttcagctaca 12600cggcccagtt ccatcccgag atatttggga tagggaatgt gagtcaagtt tatgttgaca 12660tcaagcacca actcatctgc gctgttcatg acggggataa cgccaccttg cctcgccatg 12720acaatatttc agccgtattt cagacctact accaacacca ggtcgacggc ggcaattggt 12780ttcacctgga atggctacgc cctttctttt cctcttggtt ggttttaaat gtttcgtggt 12840ttctcaggcg ttcgcctgca agccatgttt cagttcgagt ctttcggaca tcaaaaccaa 12900caccaccgca gcatcaggct tcgttgtcct ccaggacatc agctgcctta ggcatggcga 12960ctcgtcctct ccgacgattc gcaaaagttc tcagtgccgc acggcgatag ggacgcccgt 13020gtacatcacc atcactgcca atgtcacaga tgaaaattat ctacattctt ctgatctcct 13080catgctttct tcttgccttt tctatgcttc cgagatgagt gaaaagggat tcaaagtggt 13140gtttggcaat gtgtcaggca tcgtggctgt gtgcgtcaac tttaccagct acgtccaaca 13200cgtcaaggag tttacccaac gctccttagt ggtcgatcat gtgcgactgc ttcatttcat 13260gacacctgag accatgaggt gggcaaccgt tttagcctgt ctttttgcca tccctactgg 13320caatttgaat gttcaagtat gttggggaag tgcttgaccg cgtgctgttg ctcgcgattg 13380ctttttttgt ggtgtatcgt gccgtcctat cttgctgtgc tcgtcaacgc cagcaacaac 13440aacagctctc atattcagtt gatttataac ttaacgctat gtgagctgaa tggcacagat 13500tggctggcac aaaaatttga ctgggcagtg gagacttttg tcatcttccc cgtgttgact 13560cacattgttt cctatgtggc actcaccacc agccatttcc ttgacacagt tggtctggcc 13620actgtgtcca ccgccggata ttatcacggg cggtatgtct tgagtagcat ttacgcagtc 13680tgtgctctgg ctgcgctgat ttgctttgtc attaggcttg cgaagaactg catgtcctgg 13740cgctactctt gtaccagata taccaacttc cttctggaca ctaagggcaa actctatcgt 13800tggcggtcgc ccgtcattgt ggagaaaggg ggtaaggttg aggtcgaagg tcacctgatc 13860gacctcaaga gagttgtgct tgatggttcc gcggcaaccc ctttaaccag agtttcagcg 13920gaacgatggg gtcgtctcta gacgacttct gcaatgatag cacagctcca cagaaggtgc 13980ttttggcgtt ttccattacc tacacgccag tgatgatata tgctctaaag gtaagtcgcg 14040gccgactgct agggcttctg caccttttga tctttctgaa ttgtgctttt accttcgggt 14100acatgacatt cgtgcacttt gagagcacaa atagggtcgc gctcactatg ggagcagtag 14160ttgcacttct ttggggagtg tactcagcca tagaaacctg gaaattcatc acctccagat 14220gccgtttgtg cttgctaggc cgcaagtaca ttctggcccc tgcccaccac gtcgaaagtg 14280ccgcgggctt tcatccgatt gcggcaaatg ataaccacgc atttgtcgtc cggcgtcccg 14340gctccactac ggtcaacggc acattggtgc ccgggttgaa aagcctcgtg ttgggtggca 14400gaaaagctgt taagcaggga gtggtaaacc ttgttaaata tgccaaataa caacggcaag 14460cagcaaaaga aaaagaaggg gaatggccag ccagtcaatc agctgtgcca aatgctgggt 14520aagatcatcg cccaacaaaa ccagtccaga ggcaagggac cggggaagaa aaataggaag 14580aaaaacccgg ggaagcccca tttccctcta gcgactgaag atgacgtcag gcatcacttt 14640acccctagtg agcggcaatt gtgtctgtcg tcgatccaga ctgccttcaa tcagggtgct 14700ggaacttgtg ccctgtcaga ttcagggagg ataagttaca ctgtggagtt tagtttgccg 14760acgcaacata ctgtgcgtct gatccgcgcc acagcatcac cctcagcatg atgggctggc 14820attctttggc acctcagtgt tagaattggg agaatgtgtg gtgaatggca ctgattgaca 14880ctgtgcctct aagtcaccta ttcaattagg gcgaccgtgt gggggtaaag tttaattggc 14940gagaaccatg cggccgtaat taaaaa 1496642850DNAPorcine reproductive and respiratory syndrome virus 4gccggaaaga gagcaaggaa accgcgctct ggtgcgacta ctatggtcgc tcatcacgct 60tcgtccgctc atgaaacccg gcaggccacg aagcacgagg gtgccggcgc taacaaggct 120gagcatctca agcgctactc tccgcctgcc gaagggaact gtggttggca ctgcatttcc 180gccatcgcca accggatggt gaattccaac tttgagacca cccttcctga aagagtaagg 240ccttcagatg actgggccac tgacgaggat cttgtgaaca ccatccaaat cctcaggctc 300cctgcggcct tggacaggaa cggcgcttgc ggtagcgcca agtacgtgct taaactggag 360ggtgagcatt ggactgtctc tgtgatccct gggatgtccc ctactttgct cccccttgaa 420tgtgttcagg gttgttgtga gcataagggc ggtcttgttt ccccggatgc ggtcgaaatt 480tccggatttg atcctgcctg ccttgaccga ctggctaagg taatgcactt gcctagcagt 540accatcccag ccgctctggc cgaattgtcc gacgactcca accgtccggt ttccccggcc 600gctactacgt ggactgtttc gcaattctat gctcgtcata gaggaggaga tcatcatgac 660caggtgtgct tagggaaaat catcagcctt tgtcaagtta ttgaggattg ctgctgccat 720cagaataaaa ccaaccgggc tactccggaa gaggtcgcgg caaagattga tcagtacctc 780cgtggcgcaa caagtcttga ggaatgcttg gccaaacttg agagagtttc cccgccgagc 840gctgcggaca cctcctttga ttggaatgtt gtgcttcctg gggttgaggc ggcgaatcag 900acaaccgaac aacctcacgt caactcatgc tgcaccctag tccctcccgt gactcaagag 960cctttgggca aggactcggt ccctctgacc gccttctcac tgtccaattg ctattaccct 1020gcacaaggtg acgaggttca tcaccgtgag aggttaaatt ccgtactctc taagttggaa 1080gaggttgtcc tggaagaata tgggctcatg tccactggac ttggcccgcg acccgtgctg 1140ccgagcgggc tcgacgagct taaagaccag atggaggagg atctgctaaa actagccaac 1200acccaggcga cttcagaaat gatggcctgg gcggctgagc aggtcgattt aaaagcttgg 1260gtcaaaagct acccgcggtg gacaccacca cccccaccac caagagttca acctcgaaga 1320acaaagtctg tcaaaagctt gccagagggc aagcctgtcc ctgctccgcg caggaaggtc 1380agatccgatt gcggcagccc ggttttgatg ggcgacaatg tccctaacgg ttcggaagaa 1440actgtcggtg gtcccctcaa tcttccgaca ccatccgagc cgatgacacc tatgagtgag 1500cccgtacttg tgccagcgtc gcgacgtgtc cccaagctga tgacaccttt gagtgggtcg 1560gcaccagttc ctgcaccgcg tagaactgta acaacaacgc tgacgcacca ggatgagcct 1620ctggatttgt ctgcgtcctc acagacggaa tatgaggctt tccccctagc accatcgcag 1680aacatgggta tcctggaggc gggggggcaa gaagttgagg aagtcctgag tgaaatctcg 1740gatatactaa atgacaccaa ccctgcacct gtgtcatcaa gcagctccct gtcaagtgtt 1800aagatcacac gcccaaaata ctcagctcaa gccatcatcg actctggcgg gccttgcagt 1860gggcatctcc aaaaggaaaa agaagcatgc ctcagcatca tgcgtgaggc ttgtgatgcg 1920tccaagcttg gtgatcctgc tacgcaggag tggctctctc gcatgtggga tagggttgac 1980atgctgactt ggcgcaacac gtctgcttac caggcgtttc gcatcttaaa tggcaggttt 2040gagtttctcc caaagatgat tctcgagaca ccgccgcccc acccgtgcgg gtttgtgatg 2100ttacctcgca cgcctgcacc ttccgtgagt gcagagagtg acctcaccat tggttcagtg 2160gccaccgagg atgttccacg catcctcggg aaaataggag acaccgacga gctgcttgac 2220cggggtccct cggcaccctc caagggagaa ccggtctgtg accaacctgc caaagatccc 2280cggatgtcgc cgcgggagtc tgacgagagc atgatagctc cgcccgcaga tacaggtggt 2340gtcggctcat tcactgattt gccgtcttca gatggtgtgg atgtggacgg gggggggccg 2400ttaagaacgg taaaaacaaa agcaggaagg ctcttagacc aactgagctg ccaggttttt 2460agcctcgttt cccatctccc tattttcttc tcacacctct tcaaatctga cagtggttat 2520tctccgggtg attggggttt tgcagctttt actctatttt gcctctttct atgttacagt 2580tacccattct tcggttttgc tcccctcttg ggtgtatttt ctgggtcttc tcggcgtgtg 2640cgaatggggg tttttggctg ctggttggct tttgctgttg gtctgttcaa gcctgtgtcc 2700gacccagtcg gcactgcttg tgagtttgac tcgccagagt gtaggaacgt ccttcattct 2760tttgagcttc tcaaaccttg ggaccctgtc cgcagccttg ttgtgggccc cgtcggtctc 2820ggccttgcca ttcttggcag gttactgggc 285052940DNAPorcine reproductive and respiratory syndrome virus 5gctggaaaga gagcaagaaa agcacgctct tgtgcgactg ctacagtcgc tggccgcgct 60ttgtccgttc gtgaaacccg gcaggccaag gagcacgagg ttgccggcgc caacaaggct 120gagcacctca aacactactc cccgcctgcc gaagggaatt gtggttggca ctgcatttcc 180gccatcgcca accggatggt gaattccaaa tttgaaacca cccttcccga aagagtgaga 240cctccagatg actgggctac tgacgaggat cttgtgaatg ccatccaaat cctcagactc 300cctgcggcct tagacaggaa cggtgcttgt actagcgcca agtacgtact taagctggaa 360ggtgagcatt ggactgtcac tgtgacccct gggatgtccc cttctttgct ccctcttgaa 420tgtgttcagg gctgttgtgg gcacaagggc ggtcttggtt ccccagatgc agtcgaggtc 480tccggatttg accctgcctg ccttgaccgg ctggctgagg tgatgcacct gcctagcagt 540gctatcccag ccgctctggc cgaaatgtct ggcgattccg atcgttcggc ttctccggtc 600accaccgtgt ggactgtttc gcagttcttt gcccgtcaca gcggagggaa tcaccctgac 660caagtgcgct tagggaaaat tatcagcctt tgtcaggtga ttgaggactg ctgctgttcc 720cagaacaaaa ccaaccgggt caccccggag gaggtcgcag caaagattga cctgtacctc 780cgtggtgcaa caaatcttga agaatgcttg gccaggcttg agaaagcgcg cccgccacgc 840gtaatcgaca cctcctttga ttgggatgtt gtgctccctg gggttgaggc ggcaacccag 900acgatcaagc tgccccaggt caaccagtgt cgtgctctgg tccctgttgt gactcaaaag 960tccttggaca acaactcggt ccccctgacc gccttttcac tggctaacta ctactaccgt 1020gcgcaaggtg acgaagttcg tcaccgtgaa agactaaccg ccgtgctctc caagttggaa 1080aaggttgttc gagaagaata tgggctcatg ccaaccgagc ctggtccacg gcccacactg 1140ccacgcgggc tcgacgaact caaagaccag atggaggagg acttgctgaa actggctaac 1200gcccagacga cttcggacat gatggcctgg gcagtcgagc aggttgacct aaaaacttgg 1260gtcaagaact acccgcggtg gacaccacca ccccctccgc caaaagttca gcctcgaaaa 1320acgaagcctg tcaagagctt gccggagaga aagcctgtcc ccgccccgcg caggaaggtt 1380gggtccgatt gtggcagccc ggtttcatta ggcggcgatg tccctaacag ttgggaagat 1440ttggctgtta gtagcccctt tgatctcccg accccacctg agccggcaac accttcaagt 1500gagctggtga ttgtgtcctc accgcaatgc atcttcaggc cggcgacacc cttgagtgag 1560ccggctccaa ttcccgcacc tcgcggaact gtgtctcgac cggtgacacc cttgagtgag 1620ccgatccctg tgcccgcacc gcggcgtaag tttcagcagg tgaaaagatt gagttcggcg 1680gcggcaatcc caccgtacca ggacgagccc ctggatttgt ctgcttcctc acagactgaa 1740tatgaggcct ctcccccagc accgccgcag agcgggggcg ttctgggagt agaggggcat 1800gaagctgagg aaaccctgag tgaaatctcg gacatgtcgg gtaacattaa acctgcgtcc 1860gtgtcatcaa gcagctcctt gtccagcgtg agaatcacac gcccaaaata ctcagctcaa 1920gccatcatcg actcgggcgg gccctgcagt gggcatctcc aagaggtaaa ggaaacatgc 1980cttagtgtca tgcgcgaggc atgtgatgcg actaagcttg atgaccctgc tacgcaggaa 2040tggctttctc gcatgtggga tcgggtggac atgctgactt ggcgcaacac gtctgtttac 2100caggcgattt gcaccttaga tggcaggtta aagttcctcc caaaaatgat actcgagaca 2160ccgccgccct atccgtgtga gtttgtgatg atgcctcaca cgcctgcacc ttccgtaggt 2220gcggagagcg accttaccat tggctcagtt gctactgaag atgttccacg catcctcgag 2280aaaatagaaa atgtcggcga gatggccaac cagggaccct tggccttctc cgaggataaa 2340ccggtagatg accaacttgt caacgacccc cggatatcgt cgcggaggcc tgacgagagc 2400acatcagctc cgtccgcagg cacaggtggc gccggctctt ttaccgattt gccgccttca 2460gatggcgcgg atgcggacgg gggggggccg tttcggacgg taaaaagaaa agctgaaagg 2520ctctttgacc aactgagccg tcaggttttt gacctcgtct cccatctccc tgttttcttc 2580tcacgccttt tctaccctgg cggtggttat tctccgggtg attggggttt tgcagctttt 2640actctattgt gcctcttttt atgttacagt tacccagcct ttggtattgc tcccctcttg 2700ggtgtgtttt ctgggtcttc tcggcgcgtt cgaatggggg tttttggctg ctggttggct 2760tttgctgttg gtctgttcaa gcctgtgtcc gacccagtcg gcgctgcttg tgagtttgac 2820tcgccagagt gtagaaacat ccttcattct tttgagcttc tcaaaccttg ggaccctgtt 2880cgcagccttg ttgtgggccc cgtcggtctc ggtcttgcca ttcttggcag gttactgggc 29406241DNAPorcine reproductive and respiratory syndrome virus 6tttggctgtt agtagcccct ttgatctccc gaccccacct gagccggcaa caccttcaag 60tgagctggtg attgtgtcct caccgcaatg catcttcagg ccggcgacac ccttgagtga 120gccggctcca attcccgcac ctcgcggaac tgtgtctcga ccggtgacac ccttgagtga 180gccgatccct gtgcccgcac cgcggcgtaa gtttcagcag gtgaaaagat tgagttcggc 240g 241787DNAPorcine reproductive and respiratory syndrome virus 7cccttgagtg agccgatccc tgtgcccgca ccgcggcgta agtttcagca ggtgaaaaga 60ttgagttcgg cggcggcaat cccaccg 878360DNAPorcine reproductive and respiratory syndrome virus 8tcaagtgtta agatcacacg cccaaaatac tcagctcaag ccatcatcga ctctggcggg 60ccttgcagtg ggcatctcca aaaggaaaaa gaagcatgcc tcagcatcat gcgtgaggct 120tgtgatgcgt ccaagcttgg tgatcctgct acgcaggagt ggctctctcg catgtgggat 180agggttgaca tgctgacttg gcgcaacacg tctgcttacc aggcgtttcg catcttaaat 240ggcaggtttg agtttctccc aaagatgatt ctcgagacac cgccgcccca cccgtgcggg 300tttgtgatgt tacctcgcac gcctgcacct tccgtgagtg cagagagtga cctcaccatt 3609120PRTPorcine reproductive and respiratory syndrome virus 9Ser Ser Val Lys Ile Thr Arg Pro Lys Tyr Ser Ala Gln Ala Ile Ile 1 5 10 15 Asp Ser Gly Gly Pro Cys Ser Gly His Leu Gln Lys Glu Lys Glu Ala 20 25 30 Cys Leu Ser Ile Met Arg Glu Ala Cys Asp Ala Ser Lys Leu Gly Asp 35 40 45 Pro Ala Thr Gln Glu Trp Leu Ser Arg Met Trp Asp Arg Val Asp Met 50 55 60 Leu Thr Trp Arg Asn Thr Ser Ala Tyr Gln Ala Phe Arg Ile Leu Asn 65 70 75 80 Gly Arg Phe Glu Phe Leu Pro Lys Met Ile Leu Glu Thr Pro Pro Pro 85 90 95 His Pro Cys Gly Phe Val Met Leu Pro Arg Thr Pro Ala Pro Ser Val 100 105 110 Ser Ala Glu Ser Asp Leu Thr Ile 115 120 1012310DNAClassical Swine Fever Virus 10gtatacgagg ttagttcatt ctcgtataca cgattggaca aatcaaaatt ataatttggt 60tcagggcctc cctccagcga cggccgaact gggctagcca tgcccatagt aggactagca 120aaacggaggg actagccata gtggcgagct ccctgggtgg tctaagtcct gagtacagga 180cagtcgtcag tagttcgacg tgagcagaag cccacctcga gatgctacgt ggacgagggc 240atgcccaaga cacaccttaa ccctagcggg ggtcgctagg gtgaaatcac accacgtgat 300gggagtacga cctgataggg cgctgcagag gcccactatt aggctagtat aaaaatctct 360gctgtacatg gcacatggag ttgaatcact ttgaactttt atacaaaaca aacaaacaaa 420aaccaatggg agtggaggaa ccggtgtacg atgccacggg gagaccattg ttcggagacc 480cgagtgaggt acacccacaa tcaacactga agctaccaca tgataggggt agaggcaaca 540ttaaaacaac actgaagaac ctacctagga aaggcgactg caggagcggc aaccatctag 600gcccggtcag tgggatatat gtaaaacccg gccctgtctt ttaccaggac tacatgggcc 660cggtctacca tagagcccct ctggagtttt ttgacgaagt gcagttctgc gaggtgacca 720aaaggatagg tagggtgaca ggtagcgacg gaaagcttta ccatacatat gtgtgcatcg 780atggctgcat actgctgaag ctggccaaga ggggtgagcc aagaaccctg aagtggatta 840gaaatttcac cgactgtcca ttgtgggtta ccagttgctc cgatgatggc gcaagtggga 900gtaaagagaa gaagccagat aggatcaaca aaggcaaatt aaaaatagcc ccaaaagagc 960atgagaagga cagcagaact aggccacctg acgctacgat cgtggtggaa ggagtaaaat 1020accaggtcaa aaagaaaggt aaagttaaag gaaagaatac ccaagacggc ctgtaccaca 1080acaagaataa accaccagaa tccaggaaga aattagaaaa agccctattg gcatgggcgg 1140tgatagcaat tatgttgtac caaccagttg aagccgaaaa tataactcaa tggaacctga 1200gtgacaacgg cactaatggt atccagcatg ctatgtacct tagaggggtt aacagaagct 1260tgcatgggat ctggccgggg aaaatatgca aaggagtccc aacccacctg gccacagacg 1320tggagctgaa agaaatacag ggaatgatgg atgccagcga ggggacaaac tatacgtgct 1380gtaagttaca gagacatgaa tggaacaaac atggatggtg taactggcac aatatagacc 1440cctggataca gctgatgaat agaacccaag cagacttggc agaaggccct ccggtcaagg 1500agtgcgctgt gacttgcagg tacgataaag atgctgacat caacgtggtc acccaggcta 1560gaaacaggcc aacaaccctg accggctgca agaaagggaa aaatttttct tttgcgggta 1620cagttataga gagcccatgt aatttcaatg tttccgtgga ggataccttg tatggggatc 1680atgagtgcgg cagtttactc caggacgcag ctctgtacct agtagatgga atgaccaaca 1740ctatagagaa tgccagacag ggagcagcga gggtgacatc ttggctcggg aggcaactca 1800gcactgctgg gaagaggttg gagggtagaa gcaaaacctg gtttggcgct tatgccctat 1860cgccttactg taatgtaaca agcaagatag ggtacatatg gtacactaac aactgcaccc 1920cagcttgcct ccccaaaaac acaaagataa taggccctgg taaatttgac accaatgcag 1980aagacggaaa gattctccat gagatggggg gccacctatc agaatttctg ctgctttctc 2040tggttgttct gtctgacttc gcccctgaaa cagccagcgc gttatacctc attttgcact 2100acgtgattcc tcaaccccat gatgaacctg aaggctgcga tacgaaccag ctgaatctaa 2160cagtagaact caggactgaa gacgtaatac cgtcatcagt ctggaatgtt ggtgaatatg 2220tgtgtattag accagactgg tggccatatg aaaccgaggt ggctctgtta tttgaagagg 2280caggacaggt cgtaaagtta gtcttacggg cgctgaggga tttgactagg gtctggaata 2340gcgcatcaac cattgcattc ctcatctgct tgataaaagt attaagggga cagatcgtgc 2400aaggtgtggt atggctgtta ctagtaactg gggcacaagg ccggctagcc tgcaaggaag 2460attacaggta cgcaatatcg tcaaccgatg agatagggct acttggggcc ggaggtctca 2520ccaccacctg gaaggaatac aaccacgatt tgcaactgaa tgacgggacc gtcaaggcca 2580gttgcgtggc aggttccttt aaagtcacag cacttaatgt ggtcagtagg aggtatttgg 2640cgtcattgca taagaaggct ttacccactt ccgtgacatt cgagctcctg ttcgacggga 2700ccaacccatc aactgaggaa atgggagatg acttcaggtc cgggctgtgc ccgtttgata 2760cgagtcctgt tgttaaggga aagtacaata cgaccttgtt gaacggtagt gctttctatc 2820ttgtctgccc aatagggtgg acgggtgtca tagagtgcac agcagtgagc ccaacaactc 2880tgaggacaga agtggtaaag accttcagga gagacaagcc ctttccgcac agaatggatt 2940gtgtgaccac cacagtggaa aatgaagatt tattctattg taagttgggg ggcaactgga 3000catgtgtgaa aggcgagcca gtggtctaca cagggggggt agtaaaacaa tgtagatggt 3060gtggcttcga cttcgatggg cctgacggac tcccgcatta ccccataggt aagtgcattt 3120tggcaaatga gacaggttac agaatagtag attcaacgga ctgtaacaga gatggcgttg 3180taatcagcac agaggggagt catgagtgct tgatcggtaa cacgactgtc aaggtgcatg 3240catcagatga aagactgggc cctatgccat gcagacctaa agagattgtc tctagtgctg 3300gtcctgtaat gaaaacctcc tgtacattca actacacaaa aactttgaag aacaggtact 3360atgagcccag ggacagctac ttccagcaat atatgcttaa gggtgagtat cagtactggt 3420ttgacctgga tgcgactgac

cgccactcag attacttcgc agaatttgtt gtcttggtgg 3480tggtagcact gttaggagga agatatgtcc tgtggctgat agtgacctac gtagttctaa 3540cagaacaact cgccgctggt ttaccattgg gccagggtga ggtagtgttg atagggaact 3600taatcaccca cacagacatt gaggtcgtag tatatttttt actactctat ttggtcatga 3660gggatgaacc tataaagaaa tggatactgc tgctgttcca tgctatgact aacaatccag 3720tcaagaccat aacagtggca ttgctcatgg ttagtggagt tgccaagggt ggaaagatag 3780atggcggttg gcagcgactg ccggggacca gctttgacat ccaactcgcg ctgacagtta 3840tagtagtcgc tgtgatgttg ctggcaaaga gagatccgac tacggtcccc ttggttataa 3900cagtggcgac cctgagaaca gctaagatga ctaacggact tagtacggat atagccatag 3960ccacagtgtc agcagcgttg ctaacctgga cctacattag tgactattac agatacaaga 4020cctggctaca gtaccttatc agcacagtga caggtatctt tttaataagg gtactgaagg 4080gaataggtga gttggattta cacactccga ccttgccatc tcatagaccc ctctttttca 4140ttctcgtgta ccttatttcc actgcagtgg taacgagatg gaatctggac atagctggat 4200tgctgttgca gtgtgttcca acccttttga tggtttttac gatgtgggca gacattctca 4260ccctgatcct catactgccc acttacgagt taacgaagct atattatctt aaggaagtga 4320agattggggc agaaaagggc tggttatgga agaccaactt caagagggta aacgacatat 4380acgaagttga ccaagctggt gaaggggtat acctattccc gtcaaaacaa aagacaagtt 4440caatgacagg caccatgttg ccattgatca aagccatact tatcagctgc gtcagtaata 4500agtggcagtt catatatcta ctgtacttga tatttgaagt atcttactac ctccacaaga 4560agatcataga tgaaatagca ggagggacca acttcatctc aagacttgta gccgctttga 4620tcgaagtcaa ttgggccttt gacaacgaag aagttagggg tttgaagaag ttcttcctgt 4680tgtctagtag ggttaaagaa ctgatcatca aacacaaagt gaggaatgaa gtaatggtcc 4740gctggtttgg tgacgaagag gtctatggga tgccgaagtt ggttggccta gtcaaggcag 4800caacattgag taaaaataaa cattgtattt tgtgcaccgt ctgtgaagac agagagtgga 4860gaggagaaac ctgcccaaaa tgcgggcgtt ttgggccacc aatgacctgt ggcatgaccc 4920tagccgactt tgaagagaaa cactataaga ggatcttttt tagagaggat caatcagaag 4980ggccggttag ggaggagtac gcagggtatc tgcaatatag agccagaggg caattgttcc 5040tgaggaatct cccagtgcta gcaacaaaag ttaagatgct cctggtcggc aatcttggga 5100cggaggtggg agatttggaa caccttggct gggtgctcag agggcctgcc gtttgcaaga 5160aggtcactga acatgagaaa tgtaccacat ccatgatgga caaattgact gcttttttcg 5220gtgttatgcc gaggggcacc acacctagag cccctgtgag attccctacc tctctcttaa 5280agataagaag gggtttggaa actggctggg cgtacacaca ccaaggtggc atcagttcag 5340tggaccatgt cacttgtgga aaagacttac tggtatgtga cactatgggc cggacaaggg 5400ttgtttgcca gtcaaataat aagatgacag atgagtccga gtatggagtt aaaactgatt 5460ccggatgccc ggaaggagct aggtgttatg tgttcaaccc agaggcagtt aacatatcag 5520ggactaaagg agccatggtc cacttacaaa aaactggagg agaattcacc tgtgtgacag 5580catcaggaac tccggctttc tttgatctta aaaaccttaa aggctggtca gggctaccga 5640tatttgaggc atcaagtgga agggtagtcg gcagggtcaa ggtcggtaag aatgaggact 5700ctaaaccaac caagcttatg agtggaatac aaacagtttc caaaagtacc acagacttga 5760cagaaatggt aaagaaaata acgaccatga gcaggggaga attcagacaa ataacccttg 5820ctacaggtgc cggaaaaacc acggaactcc ctaggtcagt catagaagag atagggaggc 5880ataagagagt cttggtcttg atccctctga gggcggcagc agagtcagta taccaatata 5940tgagacaaaa gcatccaagc atcgcattta acctgaggat aggggagatg aaggaagggg 6000acatggccac agggataact tatgcttcat acggttactt ctgtcagatg ccacaaccta 6060agttgcgagc cgcaatggtt gagtactcct tcatattcct tgatgagtac cactgtgcca 6120cccctgaaca attggctatc atgggaaaga ttcacagatt ttcagagaac ctgcgggtgg 6180tggccatgac cgcaacacca gtaggcacgg taacgaccac agggcagaaa caccctatag 6240aagaattcat agccccagat gtgatgaaag gggaagactt aggttcagag tacttggaca 6300ttgctggact aaagatacca gtagaggaga tgaagagcaa tatgctggtt tttgtgccca 6360ccaggaacat ggcagtggag acagcaaaga aattgaaagc taagggttat aactcaggct 6420actattatag tggtgaggat ccatctaacc tgagggtggt aacatcgcag tccccgtacg 6480tggtggtggc aaccaacgcg atagaatcag gtgttactct cccggacttg gatgtggttg 6540tcgatacagg gcttaagtgt gaaaagagaa tacggctgtc acctaagatg cctttcatag 6600tgacgggcct gaagagaatg gctgtcacga ttggggaaca agcccagaga agggggagag 6660ttgggagagt aaagcctgga agatactaca ggagtcaaga aacccccgtt ggttctaaag 6720attaccatta tgatttactg caagcacaga ggtacggtat tgaagatggg ataaacatca 6780ccaaatcctt tagagagatg aactatgatt ggagccttta tgaggaggac agtctgatga 6840ttacacaatt ggaaattctt aataatttgt tgatatcaga tgaactacca atggcagtaa 6900aaaatataat ggccaggact gaccacccag aaccaattca gctggcgtac aacagctacg 6960aaacacaagt gccagtgcta ttcccaaaaa taaagaatgg agaggtgact gacagttacg 7020ataactatac cttcctcaac gcaagaaaat taggggatga tgtaccccct tacgtgtatg 7080ccacagagga tgaggactta gcggtagagc tgctgggctt agactggccg gaccctggaa 7140accaagggac cgtagagact ggcagagcac taaaacaggt agttggtcta tcaacagctg 7200agaatgccct gttagtagcc ttattcggct acgtaggata tcaggcgctt tcaaagaggc 7260atataccagt agtcacagac atatactcaa ttgaagatca caggttggaa gacaccacac 7320acctacagta cgccccaaat gctatcaaga cggaggggaa ggagacagaa ttgaaggagc 7380tagctcaggg ggatgtgcag agatgtgtgg aagccatgac caattatgca agagagggta 7440tccaatttat gaagtctcag gcactgaagg tgaaggaaac ccctacttac aaggagacaa 7500tggacactgt gacggactat gtaaagaaat tcatggaggc gctggcagac agtaaagaag 7560acatcataaa atatgggctg tgggggacgc acacagcctt atataagagc atcagtgcca 7620ggcttggggg tgagactgcg ttcgctaccc tggtagtgaa gtggctggca tttgggggtg 7680aatcaatagc agaccatgtc aaacaagcgg ccacagactt ggtcgtttac tatatcatca 7740acagacctca gttcccagga gacacggaga cacaacaaga cggaaggaaa tttgtggcca 7800gcctactggc ctcagctcta gctacttaca catacaaaag ctggaattac aataacctgt 7860ccaagatagt tgaaccggct ttggccactc tgccctatgc cgccacagct ctcaaattat 7920ttgcccccac ccgattagag agcgttgtca tattaagtac cgcaatctac aagacctacc 7980tatcaatcag gcgcggaaaa agcgatggtt tgctaggcac gggggttagt gcggctatgg 8040agatcatgtc acaaaatcca gtatccgtgg gcatagcagt catgctaggg gtaggggccg 8100tggcagccca caatgcaatc gaagccagtg agcagaaaag aacactactc atgaaagtct 8160ttgtaaagaa cttcttggac caggcagcca cagatgaatt agtcaaggag agtcctgaga 8220aaataataat ggctttgttt gaggcagtgc agacagtcgg caaccctctt agacttgtat 8280accaccttta tggagttttt tataaggggt gggaggcaaa agagttggcc caaaggacag 8340ccggtaggaa ccttttcact ttaataatgt tcgaggctgt ggaactgctg ggagtagaca 8400gtgaaggaaa ggtccgccag ctatcaagta attacatact agagcttttg tataagttcc 8460gtgacagtat caagtctagc gtgagggaga tggcaatcag ctgggcccct gcccctttca 8520gttgtgattg gacaccgacg gatgacagaa tagggctccc ccaagacaac ttccaccaag 8580tggagacgaa atgcccctgt ggttacaaga tgaaggcagt taagaattgt gctggagaac 8640tgagactctt ggaggaggaa ggttcatttc tctgcagaaa taaattcggg agaggttcac 8700ggaactacag ggtgacaaaa tattatgatg acaacctatt agaaataaag ccagtgataa 8760gaatggaagg gcatgtggaa ctctactaca agggggccac catcaaactg gatttcaaca 8820acagcaaaac aatattggca accgataaat gggaggttga tcactccact ctggtcaggg 8880tgctcaagag gcacacaggg gctggatatc atggggcata cctgggcgaa aaaccgaacc 8940acaaacacct gatagagagg gactgtgcaa ccatcaccaa agataaggtc tgttttctca 9000aaatgaagag agggtgcgca tttacttatg acttatccct tcacaacctt acccgactga 9060ttgaattggt acacaagaat aacttggaag acaaagagat tcccgctgct acggttacaa 9120cctggctggc ttacacattt gtaaatgagg atatagggac cataaaacca gccttcgggg 9180agaaagtaac gctggagatg caggaggaga taaccttgca gcctgccgtt gtggtggata 9240caacagacgt agccgtgact gtggtagggg aagcccccac tatgactaca ggggagacac 9300cgacagtgtt cgccagctca ggttcaggcc tgaaaagcca acaagttttg aaactagggg 9360taggtgaagg ccaatatcca gggactaatc cacagagggc aagcctgcac gaagccatac 9420aaggtgcaga tgagaggccc tcggtgctga tattggggtc tgataaagcc acctctaata 9480gagtgaagac tgcaaagaat gtaaaggtat acagaggcag ggacccacta gaagtgagag 9540atatgatgag gaggggaaag atcctggtcg tagccctgtc tagggttgat aatgctctat 9600tgaaatttgt tgactacaaa ggcacctttc taactaggga ggctctagag gcattaagtt 9660tgggcaggcc taaaaagaaa aacataacca aggcagaagc gcagtggttg ctgtgccccg 9720aggaccaaat ggaagagcta cccgactggt tcgcagccgg ggaacccata tttttagagg 9780ccaacattaa acatgacagg taccatctgg tgggggatat agctaccatc aaggaaaaag 9840ccaaacagtt gggggctaca gactccacaa agatatctaa ggaggttggt gccaaagtgt 9900attctatgaa actgagtaat tgggtgatgc aagaagaaaa taaacagggc aacctgaccc 9960ccttgtttga agagctcctg caacagtgtc cacccggggg ccagaacaaa accgcacaca 10020tggtctctgc ttaccaactg gctcaaggga actggatgcc gaccagctgc catgttttca 10080tggggaccat atctgccagg agaaccaaga cccacccata tgaagcatac gtaaagttaa 10140gggagttggt agaggaacac aagatgaaaa cactgtgtcc cggatcaagc ctgggtaagc 10200acaacgattg gataattgga aaaattaaat accagggaaa cctgaggacc aaacacatgt 10260tgaaccccgg caaggtggca gagcaactgt gcagagaggg acacagacac aatgtgtata 10320acaagacaat aagctcagta atgacagcta ctggtatcag gttggagaag ttgcccgtgg 10380ttagggccca gacagaccca accaacttcc accaagcaat aagggataag atagacaagg 10440aagagaacct acaaaccccg ggtttacata agaaattaat ggaagttttc aacgcattga 10500aacgacccga gttagagtcc tcctacgacg ccgtggaatg ggaggaactg gagagaggaa 10560taaacaggaa gggtgctgct ggttttttcg aacgcaaaaa tataggggaa atattggatt 10620cagagaaaaa taaagtcgaa gagattattg acaatctgaa aaaaggtaga aacattaaat 10680attatgaaac cgcgatccca aagaatgaga agagggacgt caacgatgac tggaccgccg 10740gtgatttcgt ggacgagaag aaacctagag tcatacaata ccctgaagca aaaacaagac 10800tggccatcac caaggtgatg tataagtggg tgaagcagaa gccagtagtt atacccgggt 10860atgaagggaa gacacctcta ttccaaattt ttgacaaagt gaagaaggaa tgggatcaat 10920ttcaaaatcc agtggcagtg agcttcgaca ctaaggcgtg ggacacccag gtaaccacaa 10980aagatttgga gctgataagg gacatacaaa agtattattt caagaagaaa tggcacaaat 11040ttattgacac cctgaccacg catatgtcag aagtacccgt gattagtgct gatggggaag 11100tatacataag gaaagggcaa agaggcagtg gacaacctga cacaagtgcg ggcaacagca 11160tgctaaatgt cttaacaatg gtttacgcct tctgcgaggc cacaggagta ccctacaaga 11220gctttgacag ggtggcaaaa attcatgtgt gcggggatga tggcttcctg atcacagaaa 11280gagctctcgg tgagaaattt gcaagtaagg gagtccagat cctttatgaa gctgggaagc 11340cccagaagat cactgaaggg gacaaaatga aagtggccta ccaatttgat gatattgagt 11400tttgctccca tacaccaata caagtaagat ggtcagataa cacttctagt tacatgccgg 11460ggagaaatac aaccacaatc ctggcaaaga tggccacgag gttagattcc agcggtgaaa 11520ggggtaccat agcatatgag aaagcagtag catttagctt cctgctgatg tattcctgga 11580acccactaat tagaaggatc tgcttactgg tgctatcaac tgaactgcaa gtgaaaccag 11640ggaagtcaac tacttactat tatgaaggag acccgatatc tgcctacaag gaagtcatcg 11700gccacaatct ttttgatctt aagagaacaa gctttgagaa gctggccaag ttaaatctta 11760gcatgtctgt actcggggcc tggactagac acaccagtaa aagactacta caagactgtg 11820tcaatatagg tgttaaagag ggcaactggc tagtcaatgc agacagacta gtaagtagca 11880agaccgggaa taggtacata cccggagagg gtcacaccct gcaaggaaga cattatgaag 11940aactggtgtt ggcaagaaaa cagatcaaca actttcaagg gacagacagg tacaacctag 12000gcccaatagt caacatggtg ttaaggaggc tgagagtcat gatgatgacg ctgataggga 12060gaggggcatg agcgcgggta acccgggatc tgaacccgcc agtaggaccc tattgtagat 12120aacactaatt ttcttttttc ttttttattt atttagatat tattatttat ttatttattt 12180atttattgaa tgagtaagaa ctggtataaa ctacctcaag ttaccacact acactcattt 12240ttaacagcac tttagctgga aggaaaattc ctgacgtcca cagttggact aaggtaattt 12300ctaacggccc 1231011950PRTPorcine reproductive and respiratory syndrome virus 11Ala Gly Lys Arg Ala Arg Lys Pro Arg Ser Gly Ala Thr Thr Met Val 1 5 10 15 Ala His His Ala Ser Ser Ala His Glu Thr Arg Gln Ala Thr Lys His 20 25 30 Glu Gly Ala Gly Ala Asn Lys Ala Glu His Leu Lys Arg Tyr Ser Pro 35 40 45 Pro Ala Glu Gly Asn Cys Gly Trp His Cys Ile Ser Ala Ile Ala Asn 50 55 60 Arg Met Val Asn Ser Asn Phe Glu Thr Thr Leu Pro Glu Arg Val Arg 65 70 75 80 Pro Ser Asp Asp Trp Ala Thr Asp Glu Asp Leu Val Asn Thr Ile Gln 85 90 95 Ile Leu Arg Leu Pro Ala Ala Leu Asp Arg Asn Gly Ala Cys Gly Ser 100 105 110 Ala Lys Tyr Val Leu Lys Leu Glu Gly Glu His Trp Thr Val Ser Val 115 120 125 Ile Pro Gly Met Ser Pro Thr Leu Leu Pro Leu Glu Cys Val Gln Gly 130 135 140 Cys Cys Glu His Lys Gly Gly Leu Val Ser Pro Asp Ala Val Glu Ile 145 150 155 160 Ser Gly Phe Asp Pro Ala Cys Leu Asp Arg Leu Ala Lys Val Met His 165 170 175 Leu Pro Ser Ser Thr Ile Pro Ala Ala Leu Ala Glu Leu Ser Asp Asp 180 185 190 Ser Asn Arg Pro Val Ser Pro Ala Ala Thr Thr Trp Thr Val Ser Gln 195 200 205 Phe Tyr Ala Arg His Arg Gly Gly Asp His His Asp Gln Val Cys Leu 210 215 220 Gly Lys Ile Ile Ser Leu Cys Gln Val Ile Glu Asp Cys Cys Cys His 225 230 235 240 Gln Asn Lys Thr Asn Arg Ala Thr Pro Glu Glu Val Ala Ala Lys Ile 245 250 255 Asp Gln Tyr Leu Arg Gly Ala Thr Ser Leu Glu Glu Cys Leu Ala Lys 260 265 270 Leu Glu Arg Val Ser Pro Pro Ser Ala Ala Asp Thr Ser Phe Asp Trp 275 280 285 Asn Val Val Leu Pro Gly Val Glu Ala Ala Asn Gln Thr Thr Glu Gln 290 295 300 Pro His Val Asn Ser Cys Cys Thr Leu Val Pro Pro Val Thr Gln Glu 305 310 315 320 Pro Leu Gly Lys Asp Ser Val Pro Leu Thr Ala Phe Ser Leu Ser Asn 325 330 335 Cys Tyr Tyr Pro Ala Gln Gly Asp Glu Val His His Arg Glu Arg Leu 340 345 350 Asn Ser Val Leu Ser Lys Leu Glu Glu Val Val Leu Glu Glu Tyr Gly 355 360 365 Leu Met Ser Thr Gly Leu Gly Pro Arg Pro Val Leu Pro Ser Gly Leu 370 375 380 Asp Glu Leu Lys Asp Gln Met Glu Glu Asp Leu Leu Lys Leu Ala Asn 385 390 395 400 Thr Gln Ala Thr Ser Glu Met Met Ala Trp Ala Ala Glu Gln Val Asp 405 410 415 Leu Lys Ala Trp Val Lys Ser Tyr Pro Arg Trp Thr Pro Pro Pro Pro 420 425 430 Pro Pro Arg Val Gln Pro Arg Arg Thr Lys Ser Val Lys Ser Leu Pro 435 440 445 Glu Gly Lys Pro Val Pro Ala Pro Arg Arg Lys Val Arg Ser Asp Cys 450 455 460 Gly Ser Pro Val Leu Met Gly Asp Asn Val Pro Asn Gly Ser Glu Glu 465 470 475 480 Thr Val Gly Gly Pro Leu Asn Leu Pro Thr Pro Ser Glu Pro Met Thr 485 490 495 Pro Met Ser Glu Pro Val Leu Val Pro Ala Ser Arg Arg Val Pro Lys 500 505 510 Leu Met Thr Pro Leu Ser Gly Ser Ala Pro Val Pro Ala Pro Arg Arg 515 520 525 Thr Val Thr Thr Thr Leu Thr His Gln Asp Glu Pro Leu Asp Leu Ser 530 535 540 Ala Ser Ser Gln Thr Glu Tyr Glu Ala Phe Pro Leu Ala Pro Ser Gln 545 550 555 560 Asn Met Gly Ile Leu Glu Ala Gly Gly Gln Glu Val Glu Glu Val Leu 565 570 575 Ser Glu Ile Ser Asp Ile Leu Asn Asp Thr Asn Pro Ala Pro Val Ser 580 585 590 Ser Ser Ser Ser Leu Ser Ser Val Lys Ile Thr Arg Pro Lys Tyr Ser 595 600 605 Ala Gln Ala Ile Ile Asp Ser Gly Gly Pro Cys Ser Gly His Leu Gln 610 615 620 Lys Glu Lys Glu Ala Cys Leu Ser Ile Met Arg Glu Ala Cys Asp Ala 625 630 635 640 Ser Lys Leu Gly Asp Pro Ala Thr Gln Glu Trp Leu Ser Arg Met Trp 645 650 655 Asp Arg Val Asp Met Leu Thr Trp Arg Asn Thr Ser Ala Tyr Gln Ala 660 665 670 Phe Arg Ile Leu Asn Gly Arg Phe Glu Phe Leu Pro Lys Met Ile Leu 675 680 685 Glu Thr Pro Pro Pro His Pro Cys Gly Phe Val Met Leu Pro Arg Thr 690 695 700 Pro Ala Pro Ser Val Ser Ala Glu Ser Asp Leu Thr Ile Gly Ser Val 705 710 715 720 Ala Thr Glu Asp Val Pro Arg Ile Leu Gly Lys Ile Gly Asp Thr Asp 725 730 735 Glu Leu Leu Asp Arg Gly Pro Ser Ala Pro Ser Lys Gly Glu Pro Val 740 745 750 Cys Asp Gln Pro Ala Lys Asp Pro Arg Met Ser Pro Arg Glu Ser Asp 755 760 765 Glu Ser Met Ile Ala Pro Pro Ala Asp Thr Gly Gly Val Gly Ser Phe 770 775 780 Thr Asp Leu Pro Ser Ser Asp Gly Val Asp Val Asp Gly Gly Gly Pro 785 790 795 800 Leu Arg Thr Val Lys Thr Lys Ala Gly Arg Leu Leu Asp Gln Leu Ser 805 810 815 Cys Gln Val Phe Ser Leu Val Ser His Leu Pro Ile Phe Phe Ser His 820 825 830 Leu Phe Lys Ser Asp Ser Gly Tyr Ser Pro Gly Asp Trp Gly Phe Ala 835 840 845 Ala Phe Thr Leu Phe Cys Leu Phe Leu Cys Tyr Ser Tyr Pro Phe Phe 850 855 860 Gly Phe Ala Pro Leu Leu Gly Val Phe Ser Gly Ser Ser Arg Arg Val 865 870 875 880 Arg Met Gly Val Phe Gly Cys Trp Leu Ala Phe Ala Val Gly Leu Phe 885 890 895 Lys Pro Val Ser Asp Pro Val Gly Thr Ala Cys Glu Phe Asp Ser Pro 900 905 910 Glu Cys Arg Asn Val Leu His Ser Phe Glu Leu Leu Lys Pro Trp Asp 915 920 925 Pro Val Arg Ser Leu Val Val

Gly Pro Val Gly Leu Gly Leu Ala Ile 930 935 940 Leu Gly Arg Leu Leu Gly 945 950